| Year |
Citation |
Score |
| 2024 |
Magro F, Fernandes S, Patita M, Arroja B, Lago P, Rosa I, de Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, ... ... Peyrin-Biroulet L, et al. The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients. Journal of Crohn's & Colitis. PMID 38243908 DOI: 10.1093/ecco-jcc/jjae014 |
0.319 |
|
| 2023 |
Swaminathan A, Fulforth JM, Frampton CM, Borichevsky GM, Mules TC, Kilpatrick K, Choukour M, Fields P, Ramkissoon R, Helms E, Hanauer SB, Leong RW, Peyrin-Biroulet L, Siegel CA, Gearry RB. The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease. Inflammatory Bowel Diseases. PMID 38134391 DOI: 10.1093/ibd/izad294 |
0.306 |
|
| 2023 |
Parigi TL, D'Amico F, Abreu MT, Dignass A, Dotan I, Magro F, Griffiths AM, Jairath V, Iacucci M, Mantzaris GJ, O'Morain C, Reinisch W, Sachar DB, Turner D, Yamamoto T, ... ... Peyrin-Biroulet L, et al. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. The Lancet. Gastroenterology & Hepatology. PMID 37423233 DOI: 10.1016/S2468-1253(23)00154-1 |
0.305 |
|
| 2023 |
Vieujean S, Kotze PG, Netter P, Germain A, Louis E, Danese S, Peyrin-Biroulet L. Stemming the tide with ileocaecal Crohn's disease: when is pharmacotherapy enough? Expert Opinion On Pharmacotherapy. PMID 37401098 DOI: 10.1080/14656566.2023.2232726 |
0.623 |
|
| 2023 |
Le Berre C, Danese S, Peyrin-Biroulet L. Can we change the natural course of inflammatory bowel disease? Therapeutic Advances in Gastroenterology. 16: 17562848231163118. PMID 37153497 DOI: 10.1177/17562848231163118 |
0.329 |
|
| 2022 |
Remy C, Caron B, Gouynou C, Haghnejad V, Jeanbert E, Netter P, Danese S, Peyrin-Biroulet L. Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience. Journal of Clinical Medicine. 11. PMID 36555913 DOI: 10.3390/jcm11247296 |
0.315 |
|
| 2022 |
Alfaifi J, Germain A, Heba AC, Arnone D, Gailly L, Ndiaye NC, Viennois E, Caron B, Peyrin-Biroulet L, Dreumont N. Deep Dive Into MicroRNAs in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. PMID 36545755 DOI: 10.1093/ibd/izac250 |
0.602 |
|
| 2022 |
Furfaro F, D'Amico F, Zilli A, Craviotto V, Aratari A, Bezzio C, Spinelli A, Gilardi D, Radice S, Saibeni S, Papi C, Peyrin-Biroulet L, Danese S, Fiorino G, Allocca M. Noninvasive Assessment of Postoperative Disease Recurrence in Crohn's Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 36521739 DOI: 10.1016/j.cgh.2022.11.039 |
0.308 |
|
| 2022 |
Bihain F, Caron B, Ayav A, Peyrin-Biroulet L, Laurent V, Germain A. Preoperative Magnetic Resonance Enterography to Predict Pathological Specimen Length in Crohn's Disease. Diseases of the Colon and Rectum. PMID 36102838 DOI: 10.1097/DCR.0000000000002477 |
0.706 |
|
| 2022 |
Furfaro F, Ragaini E, Peyrin-Biroulet L, Danese S. Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD). Journal of Clinical Medicine. 11. PMID 35955992 DOI: 10.3390/jcm11154374 |
0.332 |
|
| 2022 |
Renaud M, Ayav A, Caron B, Peyrin-Biroulet L, Germain A. Is Hartmann's Pouch an Option in the Management of Acute Severe Ulcerative Colitis? Journal of Clinical Medicine. 11. PMID 35807142 DOI: 10.3390/jcm11133857 |
0.697 |
|
| 2022 |
Kouki M, Caron B, Malgras A, Ayav A, Peyrin-Biroulet L, Germain A. Weight change after colectomy for ulcerative colitis. Scandinavian Journal of Gastroenterology. 1-3. PMID 35723916 DOI: 10.1080/00365521.2022.2089537 |
0.675 |
|
| 2022 |
Williams I, Pandey S, Haller W, Huynh HQ, Chan A, Düeker G, Bettels R, Peyrin-Biroulet L, Dike CR, DeGeeter C, Smith D, Al Eisa N, Platt N, Marquardt T, Schwerd T, et al. Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C. Wellcome Open Research. 7: 11. PMID 35694196 DOI: 10.12688/wellcomeopenres.16986.1 |
0.314 |
|
| 2022 |
Peyrin-Biroulet L. Mucosal Healing in Crohn's Disease and Ulcerative Colitis. Gastroenterology & Hepatology. 16: 206-208. PMID 35422679 |
0.301 |
|
| 2022 |
Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Advances in Therapy. PMID 35287234 DOI: 10.1007/s12325-022-02082-9 |
0.351 |
|
| 2022 |
Dell'Avalle C, D'Amico F, Gabbiadini R, Dal Buono A, Pugliese N, Zilli A, Furfaro F, Fiorino G, Allocca M, Peyrin-Biroulet L, Danese S. JAK inhibitors in crohn's disease: ready to go? Expert Opinion On Investigational Drugs. 31: 145-161. PMID 35164629 DOI: 10.1080/13543784.2022.2032639 |
0.316 |
|
| 2022 |
Kurt S, Caron B, Gouynou C, Netter P, Vaizey CJ, Wexner SD, Danese S, Baumann C, Peyrin-Biroulet L. Faecal incontinence in inflammatory bowel disease: The Nancy experience. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 35123908 DOI: 10.1016/j.dld.2022.01.125 |
0.342 |
|
| 2022 |
Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, ... ... Peyrin-Biroulet L, et al. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet. Gastroenterology & Hepatology. PMID 35051383 DOI: 10.1016/S2468-1253(21)00297-1 |
0.351 |
|
| 2021 |
Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therapeutic Advances in Gastroenterology. 14: 17562848211059954. PMID 34917173 DOI: 10.1177/17562848211059954 |
0.306 |
|
| 2021 |
Arnone D, Vallier M, Hergalant S, Chabot C, Ndiaye NC, Moulin D, Aignatoaei AM, Alberto JM, Louis H, Boulard O, Mayeur C, Dreumont N, Peuker K, Strigli A, Zeissig S, ... ... Peyrin-Biroulet L, et al. Long-Term Overconsumption of Fat and Sugar Causes a Partially Reversible Pre-inflammatory Bowel Disease State. Frontiers in Nutrition. 8: 758518. PMID 34869528 DOI: 10.3389/fnut.2021.758518 |
0.658 |
|
| 2021 |
Guillo L, Delanaye P, Flamant M, Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B, Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, ... ... Peyrin-Biroulet L, et al. Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 34866011 DOI: 10.1016/j.dld.2021.11.008 |
0.311 |
|
| 2021 |
Guillo L, Bonnaud G, Nahon S, Caron B, Olympie A, Laurain A, Serrero M, Buisson A, Peyrin-Biroulet L. French experience with telemedicine in inflammatory bowel disease: a patients and physicians survey. European Journal of Gastroenterology & Hepatology. PMID 34860706 DOI: 10.1097/MEG.0000000000002319 |
0.318 |
|
| 2021 |
Allocca M, Craviotto V, Dell'Avalle C, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S. Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics. PMID 34783066 DOI: 10.1111/apt.16700 |
0.304 |
|
| 2021 |
Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen MH. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology. PMID 34757139 DOI: 10.1053/j.gastro.2021.10.037 |
0.373 |
|
| 2021 |
Sousa P, Ministro P, Armuzzi A, Dignass A, Høivik ML, Barreiro-de Acosta M, Vavricka S, Saad-Hossne R, Gustavo Kotze P, Peyrin-Biroulet L, Magro F. Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 34187768 DOI: 10.1016/j.dld.2021.05.038 |
0.345 |
|
| 2021 |
Grandmougin A, D'Amico F, Remen T, Danese S, Bonneton M, Galloy MA, Peyrin-Biroulet L, Laurent V. Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease. Digestive Diseases and Sciences. PMID 34159487 DOI: 10.1007/s10620-021-07016-z |
0.314 |
|
| 2021 |
Geyl S, Guillo L, Laurent V, D'Amico F, Danese S, Peyrin-Biroulet L. Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. The Lancet. Gastroenterology & Hepatology. PMID 34090579 DOI: 10.1016/S2468-1253(21)00096-0 |
0.312 |
|
| 2021 |
Garcia KS, Facas BP, Machado MB, Teixeira FV, Avedano L, Lönnfors S, Hossne RS, Peyrin-Biroulet L, Queiroz NSF. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients. Therapeutic Advances in Gastroenterology. 14: 17562848211013249. PMID 34046083 DOI: 10.1177/17562848211013249 |
0.338 |
|
| 2021 |
Danese S, Parigi TL, Peyrin-Biroulet L, Ghosh S. Defining difficult-to-treat inflammatory bowel disease: why and how. The Lancet. Gastroenterology & Hepatology. PMID 34019799 DOI: 10.1016/S2468-1253(21)00141-2 |
0.355 |
|
| 2021 |
D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterology Journal. PMID 33961734 DOI: 10.1002/ueg2.12069 |
0.32 |
|
| 2021 |
Buisson A, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, Fumery M, Laharie D, Roblin X, Bommelaer G, Pereira B, Peyrin-Biroulet L, Vuitton L. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterology Journal. PMID 33951350 DOI: 10.1002/ueg2.12068 |
0.304 |
|
| 2021 |
Solitano V, Vuitton L, Peyrin-Biroulet L, Danese S. The Evolution of Biologics Administration From Intravenous to Subcutaneous: Treatments for Inflammatory Bowel Disease Goes Home. Gastroenterology. PMID 33773995 DOI: 10.1053/j.gastro.2021.03.038 |
0.316 |
|
| 2021 |
Lang-Schwarz C, Angeloni M, Agaimy A, Atreya R, Becker C, Dregelies T, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, ... ... Peyrin-Biroulet L, et al. Validation of the "Inflammatory Bowel Disease - Distribution, Chronicity, Activity (IBD-DCA) Score" for Ulcerative Colitis and Crohn´s disease. Journal of Crohn's & Colitis. PMID 33773497 DOI: 10.1093/ecco-jcc/jjab055 |
0.331 |
|
| 2021 |
Caron B, D'Amico F, Danese S, Peyrin-Biroulet L. Endpoints for perianal Crohn's disease trials: past, present, and future. Journal of Crohn's & Colitis. PMID 33550374 DOI: 10.1093/ecco-jcc/jjab026 |
0.3 |
|
| 2021 |
Le Berre C, Peyrin-Biroulet L. Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. Gastroenterology. PMID 33421515 DOI: 10.1053/j.gastro.2020.10.065 |
0.341 |
|
| 2021 |
D'Amico F, Peyrin-Biroulet L, Danese S. Clinical pharmacists and patients with inflammatory bowel diseases: are we ready for the multidisciplinary approach? Gastroenterology. PMID 33417937 DOI: 10.1053/j.gastro.2020.12.072 |
0.338 |
|
| 2021 |
Petitpain N, D'Amico F, Yelehe-Okouma M, Jouzeau JY, Netter P, Peyrin-Biroulet L, Gillet P. IL-17 inhibitors and inflammatory bowel diseases: a post-marketing study in Vigibase®. Clinical Pharmacology and Therapeutics. PMID 33411953 DOI: 10.1002/cpt.2155 |
0.307 |
|
| 2020 |
Lang-Schwarz C, Agaimy A, Atreya R, Becker C, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, ... ... Peyrin-Biroulet L, et al. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Archiv : An International Journal of Pathology. PMID 33373023 DOI: 10.1007/s00428-020-02982-7 |
0.354 |
|
| 2020 |
Guillo L, D'Amico F, Danese S, Peyrin-Biroulet L. Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review. Journal of Crohn's & Colitis. PMID 33367674 DOI: 10.1093/ecco-jcc/jjaa260 |
0.334 |
|
| 2020 |
Piovani D, Pansieri C, Peyrin-Biroulet L, Danese S, Bonovas S. Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study. Alimentary Pharmacology & Therapeutics. PMID 33296517 DOI: 10.1111/apt.16222 |
0.338 |
|
| 2020 |
Piovani D, Pansieri C, Peyrin-Biroulet L, Danese S, Bonovas S. Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study. Alimentary Pharmacology & Therapeutics. PMID 33296517 DOI: 10.1111/apt.16222 |
0.338 |
|
| 2020 |
D'Amico F, Peyrin-Biroulet L, Danese S, Fiorino G. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Current Opinion in Pharmacology. 55: 141-150. PMID 33254032 DOI: 10.1016/j.coph.2020.10.015 |
0.312 |
|
| 2020 |
D'Amico F, Peyrin-Biroulet L, Danese S, Fiorino G. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Current Opinion in Pharmacology. 55: 141-150. PMID 33254032 DOI: 10.1016/j.coph.2020.10.015 |
0.312 |
|
| 2020 |
Broussard D, Rivière P, Bonnet J, Fotsing G, Amiot A, Peyrin-Biroulet L, Rajca S, Buisson A, Gilleta C, Pelletier AL, Serrero M, Bouguen G, Altwegg R, Hebuterne X, Nancey S, et al. Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. Alimentary Pharmacology & Therapeutics. PMID 33241906 DOI: 10.1111/apt.16176 |
0.368 |
|
| 2020 |
Gabbiadini R, Zacharopoulou E, Furfaro F, Craviotto V, Zilli A, Gilardi D, Roda G, Loy L, Fiorino G, Peyrin-Biroulet L, Danese S, Allocca M. Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality? Current Drug Targets. PMID 33213341 DOI: 10.2174/1389450121666201119142919 |
0.337 |
|
| 2020 |
Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H, Peyrin-Biroulet L. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 33160886 DOI: 10.1016/j.dld.2020.10.018 |
0.318 |
|
| 2020 |
Gupta A, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN. Treat to target: The role of histologic healing in inflammatory bowel diseases: A systematic review and meta-analysis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 33010406 DOI: 10.1016/j.cgh.2020.09.046 |
0.375 |
|
| 2020 |
Lambin T, Amiot A, Stefanescu C, Gornet JM, Seksik P, Laharie D, Reenaers C, Bourreille A, Cadiot G, Carbonnel F, Dib N, Fumery M, Gilletta de St Joseph C, Filippi J, Viennot S, ... ... Peyrin-Biroulet L, et al. Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 32962965 DOI: 10.1016/J.Dld.2020.08.034 |
0.433 |
|
| 2020 |
Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Expert Review of Clinical Immunology. 1-10. PMID 32954893 DOI: 10.1080/1744666X.2021.1826311 |
0.381 |
|
| 2020 |
Muller M, Broséus J, Feugier P, Thieblemont C, Laurent B, Danese S, Arnone D, Ndiaye NC, Kokten T, Houlgatte R, Peyrin-Biroulet L. Characteristics Of Lymphoma In Patients With Inflammatory Bowel Disease: A Systematic Review. Journal of Crohn's & Colitis. PMID 32949235 DOI: 10.1093/Ecco-Jcc/Jjaa193 |
0.447 |
|
| 2020 |
Vaillant S, Guillo L, Michot N, D'Amico F, Germain A, Danese S, Baumann C, Rousseau H, Quilliot D, Peyrin-Biroulet L. Predictors for short bowel syndrome in Crohn's disease. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 32938546 DOI: 10.1016/J.Dld.2020.08.029 |
0.759 |
|
| 2020 |
Vaillant S, Guillo L, Michot N, D'Amico F, Germain A, Danese S, Baumann C, Rousseau H, Quilliot D, Peyrin-Biroulet L. Predictors for short bowel syndrome in Crohn's disease. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 32938546 DOI: 10.1016/j.dld.2020.08.029 |
0.31 |
|
| 2020 |
Magro F, Alves C, Lopes J, Lopes S, Tavares de Sousa H, Cotter J, Macedo da Silva V, Lago P, Vieira A, Brito M, Duarte MA, Portela F, Silva JP, Ministro P, Arroja B, ... ... Peyrin-Biroulet L, et al. Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32920215 DOI: 10.1016/J.Cgh.2020.09.017 |
0.351 |
|
| 2020 |
Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. Journal of Crohn's & Colitis. PMID 32915970 DOI: 10.1093/Ecco-Jcc/Jjaa186 |
0.442 |
|
| 2020 |
Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. Journal of Crohn's & Colitis. PMID 32915970 DOI: 10.1093/ecco-jcc/jjaa186 |
0.331 |
|
| 2020 |
Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis. Nature Reviews. Disease Primers. 6: 74. PMID 32913180 DOI: 10.1038/s41572-020-0205-x |
0.3 |
|
| 2020 |
Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. Journal of Clinical Medicine. 9. PMID 32911840 DOI: 10.3390/Jcm9092905 |
0.367 |
|
| 2020 |
Fumery M, Peyrin-Biroulet L, Nancey S, Altwegg R, Gilletta C, Veyrard P, Bouguen G, Viennot S, Poullenot F, Filippi J, Buisson A, Bozon A, Brazier F, Pouillon L, Flourie B, et al. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study. Journal of Crohn's & Colitis. PMID 32898232 DOI: 10.1093/Ecco-Jcc/Jjaa177 |
0.391 |
|
| 2020 |
Magro F, Estevinho MM, Dias CC, Correia L, Lago P, Ministro P, Portela F, Feakins R, Danese S, Peyrin-Biroulet L. Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis. Journal of Crohn's & Colitis. PMID 32898223 DOI: 10.1093/Ecco-Jcc/Jjaa176 |
0.309 |
|
| 2020 |
Solitano V, Fiorino G, D'Amico F, Peyrin-Biroulet L, Danese S. Thrombosis in IBD in the era of JAK inhibition. Current Drug Targets. PMID 32881668 DOI: 10.2174/1389450121666200902164240 |
0.355 |
|
| 2020 |
D'Amico F, Solitano V, Peyrin-Biroulet L, Danese S. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next? Expert Opinion On Biological Therapy. PMID 32857634 DOI: 10.1080/14712598.2020.1817374 |
0.436 |
|
| 2020 |
Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. PMID 32853634 DOI: 10.1053/J.Gastro.2020.08.037 |
0.381 |
|
| 2020 |
Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, Vavricka SR. Emerging treatment options for extraintestinal manifestations in IBD. Gut. PMID 32847845 DOI: 10.1136/Gutjnl-2020-322129 |
0.321 |
|
| 2020 |
Chapuis-Biron C, Kirchgesner J, Pariente B, Bouhnik Y, Amiot A, Viennot S, Serrero M, Fumery M, Allez M, Siproudhis L, Buisson A, Pineton de Chambrun G, Abitbol V, Nancey S, Caillo L, ... ... Peyrin-Biroulet L, et al. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID. The American Journal of Gastroenterology. PMID 32826571 DOI: 10.14309/Ajg.0000000000000810 |
0.412 |
|
| 2020 |
D'Amico F, Netter P, Baumann C, Veltin M, Zallot C, Aimone-Gastin I, Danese S, Peyrin-Biroulet L. Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. Journal of Clinical Medicine. 9. PMID 32825383 DOI: 10.3390/Jcm9092697 |
0.712 |
|
| 2020 |
Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? Journal of Clinical Medicine. 9. PMID 32823997 DOI: 10.3390/Jcm9082646 |
0.407 |
|
| 2020 |
Chateau T, Damico F, Zallot C, Mathieu N, Peyrin-Biroulet L. Crohn's Disease Only Visible on Small Bowel Capsule Endoscopy: A New Entity. Digestive Diseases and Sciences. PMID 32809105 DOI: 10.1007/S10620-020-06553-3 |
0.426 |
|
| 2020 |
Parigi TL, D'Amico F, Peyrin-Biroulet L, Danese S. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. Expert Opinion On Biological Therapy. 1-10. PMID 32799561 DOI: 10.1080/14712598.2020.1811849 |
0.425 |
|
| 2020 |
Guillo L, D'Amico F, Serrero M, Angioi K, Loeuille D, Costanzo A, Danese S, Peyrin-Biroulet L. Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials. United European Gastroenterology Journal. 2050640620950093. PMID 32778004 DOI: 10.1177/2050640620950093 |
0.46 |
|
| 2020 |
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Beaugerie L, Ricart E, Dewit O, Lopez-Sanroman A, ... ... Peyrin-Biroulet L, et al. Evolution of endoscopic lesions in steroid-refractory acute severe ulcerative colitis responding to infliximab or cyclosporine. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32777552 DOI: 10.1016/J.Cgh.2020.08.001 |
0.323 |
|
| 2020 |
D'Amico F, Danese S, Peyrin-Biroulet L. Systematic review on IBD patients with COVID-19: it is time to take stock. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32777550 DOI: 10.1016/J.Cgh.2020.08.003 |
0.417 |
|
| 2020 |
Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Review of Gastroenterology & Hepatology. 1-11. PMID 32762582 DOI: 10.1080/17474124.2020.1804361 |
0.441 |
|
| 2020 |
Ghosh S, Sensky T, Casellas F, Rioux LC, Ahmad T, Márquez JR, Vanasek T, Gubonina I, Sezgin O, Ardizzone S, Kligys K, Petersson J, Suzuki Y, Peyrin-Biroulet L. A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool. Journal of Crohn's & Colitis. PMID 32722760 DOI: 10.1093/Ecco-Jcc/Jjaa159 |
0.378 |
|
| 2020 |
Magro F, Rahier JF, Abeu C, MacMahon E, Hart A, van der Woude CJ, Gordon H, Adamina M, Viget N, Vavricka S, Kucharzik T, Leone S, Siegmund B, Danese S, Peyrin-Biroulet L. Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce. Journal of Crohn's & Colitis. PMID 32722754 DOI: 10.1093/Ecco-Jcc/Jjaa160 |
0.437 |
|
| 2020 |
Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, Jouzeau JY, Loeuille D, Peyrin-Biroulet L. Paradoxical gastrointestinal effects of interleukin-17 blockers. Annals of the Rheumatic Diseases. 79: 1132-1138. PMID 32719044 DOI: 10.1136/Annrheumdis-2020-217927 |
0.407 |
|
| 2020 |
D'Amico F, Danese S, Peyrin-Biroulet L. Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials. Journal of Clinical Medicine. 9. PMID 32717997 DOI: 10.3390/Jcm9082350 |
0.343 |
|
| 2020 |
Dulai PS, Peyrin-Biroulet L, Demuth D, Lasch K, Hahn KA, Lindner D, Patel H, Jairath V. Early Intervention With Vedolizumab on Longer Term Surgery Rates in Crohn's Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programs. Journal of Crohn's & Colitis. PMID 32691844 DOI: 10.1093/Ecco-Jcc/Jjaa153 |
0.406 |
|
| 2020 |
D'Amico F, Wexner SD, Vaizey CJ, Gouynou C, Danese S, Peyrin-Biroulet L. Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review. United European Gastroenterology Journal. 2050640620943699. PMID 32677555 DOI: 10.1177/2050640620943699 |
0.367 |
|
| 2020 |
Allocca M, Furfaro F, Fiorino G, Peyrin-Biroulet L, Danese S. Point-of-care ultrasound in Inflammatory Bowel Disease. Journal of Crohn's & Colitis. PMID 32674146 DOI: 10.1093/Ecco-Jcc/Jjaa151 |
0.452 |
|
| 2020 |
Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32668338 DOI: 10.1016/J.Cgh.2020.07.012 |
0.435 |
|
| 2020 |
Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflammatory Bowel Diseases. PMID 32634212 DOI: 10.1093/Ibd/Izaa078 |
0.403 |
|
| 2020 |
Ricci L, Epstein J, Buisson A, Devos C, Toussaint Y, Peyrin-Biroulet L, Guillemin F. Flare-IBD: development and validation of a questionnaire based on patients' messages on an internet forum for early detection of flare in inflammatory bowel disease: study protocol. Bmj Open. 10: e037211. PMID 32611745 DOI: 10.1136/Bmjopen-2020-037211 |
0.469 |
|
| 2020 |
Daude S, Gastin I, Peyrin-Biroulet L. Editorial: diagnostic precision of iron deficiency in inflammatory bowel disease. Authors' reply. Alimentary Pharmacology & Therapeutics. 52: 401. PMID 32592250 DOI: 10.1111/Apt.15832 |
0.366 |
|
| 2020 |
Gilardi D, Gabbiadini R, Allocca M, Correale C, Fiorino G, Furfaro F, Zilli A, Peyrin-Biroulet L, Danese S. PK, PD and interactions: the new scenario with JAK inhibitors and S1P Receptor Modulators, two classes of small molecule drugs, in IBD. Expert Review of Gastroenterology & Hepatology. PMID 32571107 DOI: 10.1080/17474124.2020.1785868 |
0.36 |
|
| 2020 |
D'Amico F, Peyrin-Biroulet L, Vandromme L, Bouhnik Y, Faure P, Nahon S, Hagege H, Hebuterne X, Benkhalifa S, Nachury M. Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 32532602 DOI: 10.1016/J.Dld.2020.05.032 |
0.422 |
|
| 2020 |
Furfaro F, Vuitton L, Fiorino G, Koch S, Allocca M, Gilardi D, Zilli A, D'Amico F, Radice S, Chevaux JB, Schaefer M, Chaussade S, Danese S, Peyrin-Biroulet L. SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nature Reviews. Gastroenterology & Hepatology. PMID 32528139 DOI: 10.1038/S41575-020-0319-3 |
0.362 |
|
| 2020 |
Sebastian S, Gonzalez HA, Peyrin-Biroulet L. Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD. Journal of Crohn's & Colitis. PMID 32520312 DOI: 10.1093/Ecco-Jcc/Jjaa120 |
0.399 |
|
| 2020 |
Reinisch W, Danese S, Peyrin-Biroulet L, Loftus EV. Clinical trials for inflammatory bowel disease: a global guidance during COVID-19 pandemic. Journal of Crohn's & Colitis. PMID 32520311 DOI: 10.1093/Ecco-Jcc/Jjaa119 |
0.393 |
|
| 2020 |
Piovani D, Pansieri C, Peyrin-Biroulet L, Danese S, Bonovas S. A snapshot of the ongoing clinical research on COVID-19. F1000research. 9: 373. PMID 32518636 DOI: 10.12688/F1000Research.23843.1 |
0.306 |
|
| 2020 |
Zacharopoulou E, Craviotto V, Fiorino G, Furfaro F, Zilli A, Gilardi D, Peyrin-Biroulet L, Danese S, Allocca M. Targeting the gut layers in Crohn's disease: mucosal or transmural healing? Expert Review of Gastroenterology & Hepatology. 1-13. PMID 32515627 DOI: 10.1080/17474124.2020.1780914 |
0.389 |
|
| 2020 |
Magro F, Doherty G, Peyrin-Biroulet L, Svrcek M, Borralho P, Walsh A, Carneiro F, Rosini F, de Hertogh G, Biedermann L, Pouillon L, Scharl M, Tripathi M, Danese S, Villanacci V, et al. ECCO Position Paper: Harmonisation of the approach to Ulcerative Colitis Histopathology. Journal of Crohn's & Colitis. PMID 32504534 DOI: 10.1093/Ecco-Jcc/Jjaa110 |
0.347 |
|
| 2020 |
D'Amico F, Chateau T, Laurent V, Danese S, Peyrin-Biroulet L. Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity? Journal of Clinical Medicine. 9. PMID 32498279 DOI: 10.3390/Jcm9061691 |
0.361 |
|
| 2020 |
Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, et al. Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs. PMID 32488813 DOI: 10.1007/S40265-020-01333-9 |
0.36 |
|
| 2020 |
Danese S, Sands B, Ng SC, Peyrin-Biroulet L. The day after COVID-19 in IBD: how to go back to 'normal'. Nature Reviews. Gastroenterology & Hepatology. PMID 32483356 DOI: 10.1038/S41575-020-0322-8 |
0.418 |
|
| 2020 |
Pouillon L, Remen T, Amicone C, Louis E, Maes S, Reenaers C, Germain A, Baumann C, Bossuyt P, Peyrin-Biroulet L. Risk of Late Post-Operative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32445951 DOI: 10.1016/J.Cgh.2020.05.027 |
0.646 |
|
| 2020 |
Boube M, Laharie D, Nancey S, Hebuterne X, Fumery M, Pariente B, Roblin X, Peyrin-Biroulet L, Minet-Quinard R, Pereira B, Bommelaer G, Buisson A. Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 32444250 DOI: 10.1016/J.Dld.2020.03.020 |
0.397 |
|
| 2020 |
Fiorino G, Peyrin-Biroulet L, Danese S. Protecting patients with IBD during the COVID-19 pandemic. The Lancet. Gastroenterology & Hepatology. PMID 32442545 DOI: 10.1016/S2468-1253(20)30152-7 |
0.329 |
|
| 2020 |
D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S. Long-term safety of approved biologics for ulcerative colitis. Expert Opinion On Drug Safety. PMID 32441228 DOI: 10.1080/14740338.2020.1773430 |
0.462 |
|
| 2020 |
D'Amico F, Peyrin-Biroulet L, Danese S. Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. Journal of Clinical Medicine. 9. PMID 32438763 DOI: 10.3390/Jcm9051536 |
0.31 |
|
| 2020 |
D'Amico F, Fiorino G, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L, Danese S. Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Review of Gastroenterology & Hepatology. 1-9. PMID 32427002 DOI: 10.1080/17474124.2020.1772057 |
0.436 |
|
| 2020 |
Kotze PG, Peyrin-Biroulet L, Danese S. Balancing risks and benefits in inflammatory bowel disease patients during the COVID-19 pandemic. Gastroenterology. PMID 32422207 DOI: 10.1053/J.Gastro.2020.04.075 |
0.442 |
|
| 2020 |
D'Amico F, Rahier JF, Leone S, Peyrin-Biroulet L, Danese S. Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. The Lancet. Gastroenterology & Hepatology. PMID 32411920 DOI: 10.1016/S2468-1253(20)30151-5 |
0.453 |
|
| 2020 |
Lasa J, Correa G, Fuxman C, Garbi L, Linares ME, Lubrano P, Rausch A, Toro M, Yantorno M, Zubiaurre I, Peyrin-Biroulet L, Olivera P. Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study. Gastroenterology Research and Practice. 2020: 4060648. PMID 32411197 DOI: 10.1155/2020/4060648 |
0.445 |
|
| 2020 |
Bonnaud G, Bouhnik Y, Hagege H, Hebuterne X, Pariente B, Roblin X, Peyrin-Biroulet L. Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 32402743 DOI: 10.1016/J.Dld.2020.03.033 |
0.395 |
|
| 2020 |
D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A practical guide for faecal calprotectin measurement: myths and realities. Journal of Crohn's & Colitis. PMID 32392336 DOI: 10.1093/Ecco-Jcc/Jjaa093 |
0.349 |
|
| 2020 |
Bossuyt P, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslembrouck R, Laurent V, Zappa M, Savoye-Collet C, Pariente B, Filippi J, Baert F, D'haens G, Laharie D, Peyrin-Biroulet L, et al. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32360982 DOI: 10.1016/J.Cgh.2020.04.052 |
0.435 |
|
| 2020 |
Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, Danese S, Peyrin-Biroulet L. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32360811 DOI: 10.1016/J.Cgh.2020.04.071 |
0.398 |
|
| 2020 |
D'Amico F, Danese S, Peyrin-Biroulet L. Inflammatory bowel disease management during the COVID-19 outbreak: a survey from the European Crohn's and Colitis Organization (ECCO). Gastroenterology. PMID 32360567 DOI: 10.1053/J.Gastro.2020.04.059 |
0.422 |
|
| 2020 |
D'Amico F, Pugliese N, Peyrin-Biroulet L, Danese S. Efficacy of anti-TNFα drugs in patients with stricturing Crohn's disease. Expert Review of Gastroenterology & Hepatology. PMID 32351139 DOI: 10.1080/17474124.2020.1759417 |
0.438 |
|
| 2020 |
Germain A, Chateau T, Beyer-Berjot L, Zerbib P, Lakkis Z, Amiot A, Buisson A, Laharie D, Lefèvre JH, Nancey S, Stefanescu C, Bresler L, Peyrin-Biroulet L. Surgery for Crohn's disease during pregnancy: A nationwide survey. United European Gastroenterology Journal. 2050640620921060. PMID 32326876 DOI: 10.1177/2050640620921060 |
0.611 |
|
| 2020 |
Daude S, Remen T, Chateau T, Danese S, Gastin I, Baumann C, Gueant JL, Peyrin-Biroulet L. Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. PMID 32323356 DOI: 10.1111/Apt.15739 |
0.554 |
|
| 2020 |
D'Amico F, Peyrin-Biroulet L, Danese S. Inflammatory bowel diseases and COVID-19: the invisible enemy. Gastroenterology. PMID 32305331 DOI: 10.1053/J.Gastro.2020.04.032 |
0.455 |
|
| 2020 |
Peyrin-Biroulet C, D'Amico F, Peyrin-Biroulet L. Will COVID-19 infection be less severe in ulcerative colitis than in Crohn's patients due to a lower rate of smokers? Journal of Crohn's & Colitis. PMID 32303741 DOI: 10.1093/Ecco-Jcc/Jjaa077 |
0.341 |
|
| 2020 |
Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nature Reviews. Gastroenterology & Hepatology. PMID 32303700 DOI: 10.1038/S41575-020-0293-9 |
0.344 |
|
| 2020 |
Amiot A, Filippi J, Abitbol V, Cadiot G, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Alimentary Pharmacology & Therapeutics. PMID 32291786 DOI: 10.1111/Apt.15717 |
0.329 |
|
| 2020 |
Muller M, Hansmannel F, Arnone D, Choukour M, Ndiaye NC, Kokten T, Houlgatte R, Peyrin-Biroulet L. Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer. United European Gastroenterology Journal. 2050640620919254. PMID 32268844 DOI: 10.1177/2050640620919254 |
0.367 |
|
| 2020 |
Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease. Nature Reviews. Disease Primers. 6: 22. PMID 32242028 DOI: 10.1038/s41572-020-0156-2 |
0.354 |
|
| 2020 |
Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, ... ... Peyrin-Biroulet L, et al. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology. PMID 32224129 DOI: 10.1053/J.Gastro.2020.03.039 |
0.425 |
|
| 2020 |
Chateau T, Peyrin-Biroulet L. Evolving therapeutic goals in Crohn's disease management. United European Gastroenterology Journal. 8: 133-139. PMID 32213074 DOI: 10.1177/2050640619887316 |
0.434 |
|
| 2020 |
Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, Fumery M, Bouguen G, Peyrin-Biroulet L, Bourreille A, Caillo L, Simon M, Goutorbe F, Laharie D. Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Alimentary Pharmacology & Therapeutics. PMID 32201971 DOI: 10.1111/Apt.15680 |
0.349 |
|
| 2020 |
Danese S, Schabel E, Ainsworth MA, Peyrin-Biroulet L. Challenges and opportunities for IBD drug development: from early stage to regulatory approval. Gut. PMID 32179569 DOI: 10.1136/Gutjnl-2019-320542 |
0.324 |
|
| 2020 |
Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F. Treatment Algorithms for Crohn's Disease. Digestion. 1-15. PMID 32172251 DOI: 10.1159/000506364 |
0.446 |
|
| 2020 |
Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Bonovas S. Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. PMID 32170782 DOI: 10.1111/Apt.15692 |
0.418 |
|
| 2020 |
Peppas S, Piovani D, Peyrin-Biroulet L, Danese S, Bonovas S. Statins and inflammatory bowel disease: Where do we stand? European Journal of Internal Medicine. PMID 32151491 DOI: 10.1016/J.Ejim.2020.02.017 |
0.452 |
|
| 2020 |
Pugliese N, Roda G, Peyrin-Biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion On Emerging Drugs. 1-9. PMID 32148112 DOI: 10.1080/14728214.2020.1737009 |
0.377 |
|
| 2020 |
Chapuis-Biron C, Bourrier A, Nachury M, Nancey S, Bouhnik Y, Serrero M, Armengol-Debeir L, Buisson A, Tran-Minh ML, Zallot C, Fumery M, Bouguen G, Abitbol V, Viennot S, Chanteloup E, ... ... Peyrin-Biroulet L, et al. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. Alimentary Pharmacology & Therapeutics. 51: 719-727. PMID 32080886 DOI: 10.1111/Apt.15665 |
0.433 |
|
| 2020 |
Vuitton L, Peyrin-Biroulet L. Pharmacological Prevention of Postoperative Recurrence in Crohn's Disease. Drugs. PMID 32056142 DOI: 10.1007/S40265-020-01266-3 |
0.392 |
|
| 2020 |
D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. Review article: faecal calprotectin and histologic remission in ulcerative colitis. Alimentary Pharmacology & Therapeutics. PMID 32048751 DOI: 10.1111/Apt.15662 |
0.336 |
|
| 2020 |
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. PMID 32044319 DOI: 10.1053/J.Gastro.2020.01.047 |
0.364 |
|
| 2020 |
Fiorino G, Allocca M, Correale C, Roda G, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Danese S. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. Expert Opinion On Biological Therapy. 1-7. PMID 32027523 DOI: 10.1080/14712598.2020.1727437 |
0.368 |
|
| 2020 |
Saadah OI, Fallatah KB, Baumann C, Elbaradie AA, Howladar FT, Daiwali MT, Alshuaibi OH, Alsahafi MA, Bokhary RY, Qari YA, Peyrin-Biroulet L, Mosli MH. Histologically confirmed upper gastrointestinal Crohn's disease: is it rare or are we just not searching hard enough? Intestinal Research. PMID 32019291 DOI: 10.5217/Ir.2019.00091 |
0.405 |
|
| 2020 |
Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, et al. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs. PMID 32002851 DOI: 10.1007/S40265-020-01256-5 |
0.383 |
|
| 2020 |
Tavares De Sousa H, Estevinho MM, Peyrin-Biroulet L, Danese S, Dias CC, Carneiro F, Magro F. Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. Journal of Crohn's & Colitis. PMID 31985012 DOI: 10.1093/Ecco-Jcc/Jjz178 |
0.38 |
|
| 2020 |
Danese S, Fiorino G, Peyrin-Biroulet L. Positioning therapies in ulcerative colitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31982609 DOI: 10.1016/J.Cgh.2020.01.017 |
0.378 |
|
| 2020 |
Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE, Vedrines P, Duru G, Peyrin-Biroulet L, Nancey S, Flourie B, Paul S. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut. PMID 31980448 DOI: 10.1136/Gutjnl-2019-319758 |
0.347 |
|
| 2020 |
Lagrange J, Lacolley P, Wahl D, Peyrin-Biroulet L, Regnault V. Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31972287 DOI: 10.1016/J.Cgh.2019.12.043 |
0.4 |
|
| 2020 |
D'Amico F, Danese S, Peyrin-Biroulet L. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? Expert Opinion On Biological Therapy. 1-9. PMID 31951748 DOI: 10.1080/14712598.2020.1717465 |
0.328 |
|
| 2020 |
Martin A, Nachury M, Peyrin-Biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, et al. Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study. Journal of Crohn's & Colitis. PMID 31930285 DOI: 10.1093/Ecco-Jcc/Jjaa005 |
0.484 |
|
| 2020 |
Olivera P, Lasa J, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis. Gastroenterology. PMID 31926171 DOI: 10.1053/J.Gastro.2020.01.001 |
0.443 |
|
| 2020 |
D'Amico F, Baumann C, Rousseau H, Danese S, Peyrin-Biroulet L. Phase 1, 2 and 3 trials in inflammatory bowel diseases: a practical guide for the non-specialist. Journal of Crohn's & Colitis. PMID 31901097 DOI: 10.1093/Ecco-Jcc/Jjz214 |
0.32 |
|
| 2020 |
Parigi TL, Roda G, Argollo M, Gilardi D, Danese S, Peyrin-Biroulet L. Is there a role for therapeutic sphingolipids in inflammatory bowel disease Expert Review of Gastroenterology & Hepatology. 14: 47-54. PMID 31874053 DOI: 10.1080/17474124.2020.1709446 |
0.451 |
|
| 2020 |
Amiot A, Vered A, Filippi J, Cadiot G, Laharie D, Melanie S, Altwegg R, Bouhnik Y, Peyrin-biroulet L, Gilletta C, Roblin X, chambrun GPd, Vuitton L, Bourrier A, Nancey S, et al. P719 Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.847 |
0.313 |
|
| 2020 |
Li K, Yang F, Marano C, Zhang H, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friendman JR, Hertogh GD. P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.840 |
0.314 |
|
| 2020 |
Rayer C, Roblin X, Laharie D, Caron B, Flamant M, Dewitte M, Fumery M, Viennot S, Bourreille A, Pariente B, Siproudhis L, Peyrin-Biroulet L, Bouguen G. P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.793 |
0.349 |
|
| 2020 |
Schwartz D, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. P476 Efficacy and safety of 2 vedolizumab IV regimens in patients with perianal fistulising Crohn’s disease: results of the ENTERPRISE study Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.605 |
0.356 |
|
| 2020 |
Danese S, Panaccione R, Peyrin-Biroulet L, Marano C, O’Brien CD, Zhang H, Zhou Y, Johanns J, Scherl E, Leong RWL, Rowbotham DS, Arasaradnam RP, Sands BE. P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.577 |
0.313 |
|
| 2020 |
Buisson A, Fumery M, Serrero M, Orsat L, Nancey S, Rivière P, Altwegg R, Peyrin-Biroulet L, Nachury M, Hébuterne X, Gilletta C, Flamant M, Viennot S, Bouguen G, Amiot A, et al. P355 Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2) Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.484 |
0.438 |
|
| 2020 |
DAUDE S, Remen T, Chateau T, Danese S, Gastin I, Baumann C, Gueant JL, Peyrin-Biroulet L. P309 Ferritin or transferrin saturation vs. soluble transferrin receptor for iron deficiency diagnosis in inflammatory bowel disease Journal of Crohn's and Colitis. 14: S309-S309. DOI: 10.1093/Ecco-Jcc/Jjz203.438 |
0.318 |
|
| 2020 |
Allocca M, Fiorino G, Furfaro F, Zilli A, Gilardi D, Radice S, Peyrin-Biroulet L, Danese S. P273 Point-of-care bowel ultrasound for detecting ileocolonic inflammation in Crohn’s disease Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.402 |
0.34 |
|
| 2020 |
Tadbiri S, Nachury M, Bouhnik Y, Serrero M, Jerome F, Roblin X, Bourrier A, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abtibol, Reimund JM, ... ... Peyrin-Biroulet L, et al. P248 Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.377 |
0.433 |
|
| 2020 |
Fiorino G, Gilardi D, Bonovas S, Sabatino AD, Angeli E, Gaffuri N, Allocca M, Furfaro F, Roda G, Lenti M, Nicola A, Mengoli C, Peyrin-Biroulet L, Danese S. P244 Validation of the Red Flags index for early diagnosis of Crohn’s disease: A prospective general practitioner study Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.373 |
0.328 |
|
| 2020 |
Ungaro R, Jordan R, Yzet C, Bossuyt P, Baert F, Vanasek T, D’Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, ... ... Peyrin-Biroulet L, et al. P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn’s disease: Data from the CALM study Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.369 |
0.372 |
|
| 2020 |
Dulai P, Singh S, Jairath V, Ma C, Narula N, Casteele NV, Peyrin-Biroulet L, Vermeire S, D’Haens G, Feagan B, Sandborn W. P120 Prevalence of endoscopic improvement and endoscopic remission according to patient reported outcomes in ulcerative colitis Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.249 |
0.339 |
|
| 2020 |
Sandborn W, Panés J, Peyrin-Biroulet L, Louis E, Greenbloom S, Zhou W, Zhou Q, Liu J, Lacerda AP. DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.118 |
0.345 |
|
| 2020 |
Fiorino G, Allocca M, Gilardi D, Alfieri M, Danieli P, Furfaro F, Roda G, Loy L, Zilli A, Radice S, Peyrin-Biroulet L, Danese S. DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.102 |
0.379 |
|
| 2020 |
Danese S, Vermeire S, D’Haens G, Panés J, Dignass A, Magro F, Nazar M, Bars ML, Sloan S, Lahaye M, Ni L, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, ... ... Peyrin-Biroulet L, et al. DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.052 |
0.341 |
|
| 2020 |
Colombel JF, Panés J, D’Haens G, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV, Danese S, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Lefebvre J, Doan T, Xie W, et al. OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study Journal of Crohns & Colitis. 14. DOI: 10.1093/Ecco-Jcc/Jjz203.000 |
0.366 |
|
| 2020 |
Rubin DT, Peyrin-Biroulet L, Reinisch W, Tole S, Sullivan L, Park KT, Regueiro MD. P003 Inflammatory Bowel Disease Patients’ Perspectives Of Clinical Trials Gastroenterology. 158. DOI: 10.1053/J.Gastro.2019.11.214 |
0.408 |
|
| 2020 |
Pouillon L, Amicone C, remen t, Louis E, Maes S, Reenaers C, Germain A, Baumann C, Bossuyt P, Peyrin-Biroulet L. Tu1891 RISK OF LATE POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE IN ENDOSCOPIC REMISSION AFTER ILEOCAECAL RESECTION: A 10-YEAR MULTICENTER EXPERIENCE Gastroenterology. 158: S-1206. DOI: 10.1016/S0016-5085(20)33678-7 |
0.634 |
|
| 2020 |
Sands BE, Panaccione R, Peyrin-Biroulet L, Marano CW, O'Brien CD, Zhang H, Zhou Y, Johanns J, Scherl EJ, Leong RW, Rowbotham D, Arasaradnam RP, Danese S. Tu1886 DOSE ADJUSTMENT IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE UNIFI MAINTENANCE STUDY LONG-TERM EXTENSION Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)33673-8 |
0.31 |
|
| 2020 |
Danese S, Vermeire S, D'Haens GR, Panes J, Dignass A, Magro F, Nazar M, Bars ML, Sloan S, Lahaye M, Ni L, Daperno M, Lukas M, Armuzzi A, Löwenberg M, ... ... Peyrin-Biroulet L, et al. Tu1864 ENDOSCOPIC RESPONSE TO INDUCTION WITH USTEKINUMAB IN CROHN'S DISEASE: STARDUST INTERIM ANALYSIS Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)33651-9 |
0.401 |
|
| 2020 |
Li K, Yang F, Marano CW, Zhang H, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman J, Hertogh GD. Tu1860 ASSOCIATION OF HISTOLOGIC-ENDOSCOPIC MUCOSAL HEALING AFTER USTEKINUMAB INDUCTION OR MAINTENANCE THERAPY WITH 2-YEAR OUTCOMES IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)33647-7 |
0.311 |
|
| 2020 |
Sandborn WJ, Panes J, Peyrin-Biroulet L, Louis E, Greenbloom S, Zhou W, Zhou Q, Liu J, Lacerda AP. Tu1850 DOSE ESCALATION OF UPADACITINIB IN CROHN'S DISEASE PATIENTS WITH INADEQUATE RESPONSE: DATA FROM THE RANDOMISED CELEST STUDY Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)33637-4 |
0.379 |
|
| 2020 |
Sandborn WJ, Sands BE, Panaccione R, Marano CW, O'Brien CD, Zhang H, Johanns J, Zhou Y, Peyrin-Biroulet L, Hisamatsu T, Danese S. Tu1848 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 2 YEARS: RESULTS OF THE UNIFI MAINTENANCE STUDY AND LONGTERM EXTENSION Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)33635-0 |
0.328 |
|
| 2020 |
Rayer C, Roblin X, Laharie D, Flamant M, Dewitte M, Fumery M, Caron B, Viennot S, Pariente B, Laurent S, Peyrin-Biroulet L, Bouguen G. Mo1873 WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)33072-9 |
0.382 |
|
| 2020 |
Ungaro RC, Jordan R, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Olga P, Goldis A, ... ... Peyrin-Biroulet L, et al. Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)32438-0 |
0.394 |
|
| 2020 |
Allocca M, Fiorino G, Furfaro F, Zilli A, Gilardi D, Radice S, Peyrin-Biroulet L, Danese S. Su1887 POINT-OF-CARE BOWEL ULTRASOUND FOR DETECTING ILEO-COLONIC INFLAMMATION IN CROHN'S DISEASE. Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)32414-8 |
0.378 |
|
| 2020 |
Fiorino G, Gilardi D, Bonovas S, Sabatino AD, Lenti M, Aronico N, Mengoli C, Angeli E, Gaffuri N, Allocca M, Furfaro F, Roda G, Peyrin-Biroulet L, Danese S. Su1871 VALIDATION OF THE RED FLAGS INDEX FOR EARLY DIAGNOSIS OF CROHN'S DISEASE: A PROSPECTIVE GENERAL PRACTITIONER STUDY Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)32398-2 |
0.369 |
|
| 2020 |
Fiorino G, Allocca M, Gilardi D, Alfieri MF, Danieli P, Furfaro F, Roda G, Loy L, Zilli A, Radice S, Peyrin-Biroulet L, Danese S. Sa1793 EFFICACY AND SAFETY OF IRON CARBOXYMALTOSE ON CHRONIC FATIGUE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RANDOMIZED CONTROLLED TRIAL Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)31753-4 |
0.375 |
|
| 2020 |
Buisson A, Fumery M, Serrero M, Orsat L, Nancey S, Rivière P, Altwegg R, Peyrin-Biroulet L, Nachury M, Hebuterne X, Gilletta C, Flamant M, Viennot S, Bouguen G, Amiot A, et al. Sa1744 IMPACT OF LINE OF THERAPY, THERAPEUTIC ESCALATION OR DE-ESCALATION ON ACCEPTABILITY OF TREATMENT REGIMEN IN INFLAMMATORY BOWEL DISEASE: A SUB-ANALYSIS FROM THE PROSPECTIVE NATIONWIDE STUDY ACCEPT2. Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)31706-6 |
0.404 |
|
| 2020 |
Buisson A, Fumery M, Serrero M, Orsat L, Nancey S, Rivière P, Altwegg R, Peyrin-Biroulet L, Nachury M, Hebuterne X, Gilletta C, Flamant M, Viennot S, Bouguen G, Amiot A, et al. Sa1743 ACCEPTABILITY OF TREATMENT REGIMEN IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM A PROSPECTIVE NATIONWIDE STUDY (ACCEPT2). Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)31705-4 |
0.451 |
|
| 2020 |
Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. 949 Efficacy And Safety Of 2 Vedolizumab Iv Regimens In Patients With Perianal Fistulizing Crohn'S Disease: Results Of The Enterprise Study Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)31166-5 |
0.389 |
|
| 2020 |
Pariente B, D'Haens GR, Peyrin-Biroulet L, Duveau N, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Woude CJVD, Buisson A, Hootegem PV, Allez M, Filippi J, Brixi H, Giletta C, et al. 946 Deep Remission At 1 Year Is Not Associated With Better Outcome In Crohn'S Disease: Long-Term Data From Tailorix Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)31163-X |
0.346 |
|
| 2020 |
Colombel JF, Panes J, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV, Danese S, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Lefebvre J, Doan T, Xie W, et al. 945 Higher Versus Standard Adalimumab Maintenance Regimens In Patients With Moderately To Severely Active Ulcerative Colitis: Results From The Serene-Uc Maintenance Study Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)31162-8 |
0.366 |
|
| 2019 |
Chateau T, Peyrin-Biroulet L. [Thiopurines in inflammatory bowel disease: what's new ?] La Revue Du Praticien. 69: 819-825. PMID 32237642 |
0.339 |
|
| 2019 |
Dulai PS, Amiot A, Peyrin-Biroulet L, Jairaith V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, et al. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Alimentary Pharmacology & Therapeutics. PMID 31867766 DOI: 10.1111/Apt.15609 |
0.364 |
|
| 2019 |
Fauny M, D'Amico F, Bonovas S, Netter P, Danese S, Loeuille D, Peyrin-Biroulet L. Fecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review. Journal of Crohn's & Colitis. PMID 31858121 DOI: 10.1093/Ecco-Jcc/Jjz205 |
0.418 |
|
| 2019 |
Algethmi W, Baumann C, Alnajjar W, Sroji A, Alsahafi M, Jawa H, Qari Y, Peyrin-Biroulet L, Saadah OI, Mosli M. Environmental exposures and the risk of inflammatory bowel disease: a case-control study from Saudi Arabia. European Journal of Gastroenterology & Hepatology. PMID 31851095 DOI: 10.1097/Meg.0000000000001619 |
0.392 |
|
| 2019 |
Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frédéric Colombel J, Rossiter G, Usiskin K, Ather S, Zhan X, DʼHaens G. Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. The American Journal of Gastroenterology. PMID 31850931 DOI: 10.14309/Ajg.0000000000000493 |
0.383 |
|
| 2019 |
Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S. Histological healing: should it be considered as a new outcome for ulcerative colitis? Expert Opinion On Biological Therapy. PMID 31847610 DOI: 10.1080/14712598.2020.1701652 |
0.395 |
|
| 2019 |
Peyrin-Biroulet L, Lönnfors S, Avedano L, Danese S. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey. United European Gastroenterology Journal. 7: 1345-1352. PMID 31839960 DOI: 10.1177/2050640619883704 |
0.445 |
|
| 2019 |
Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United European Gastroenterology Journal. 7: 1285-1303. PMID 31839954 DOI: 10.1177/2050640619883566 |
0.416 |
|
| 2019 |
Allen PB, Bonovas S, Danese S, Peyrin-Biroulet L. Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. Expert Opinion On Biological Therapy. PMID 31815548 DOI: 10.1080/14712598.2020.1702020 |
0.409 |
|
| 2019 |
Allocca M, Danese S, Laurent V, Peyrin-Biroulet L. Use of Cross-sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31812657 DOI: 10.1016/J.Cgh.2019.11.052 |
0.4 |
|
| 2019 |
D'Amico F, Pouillon L, Argollo M, Hart A, Fiorino G, Vegni E, Radice S, Gilardi D, Fazio M, Leone S, Bonovas S, Magro F, Danese S, Peyrin-Biroulet L. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 31812570 DOI: 10.1016/J.Dld.2019.11.004 |
0.377 |
|
| 2019 |
Chateau T, Feakins R, Marchal-Bressenot A, Magro F, Danese S, Peyrin-Biroulet L. Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. The American Journal of Gastroenterology. PMID 31809296 DOI: 10.14309/Ajg.0000000000000437 |
0.379 |
|
| 2019 |
Chateau T, Peyrin-Biroulet L. Two Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks. Inflammatory Bowel Diseases. PMID 31769497 DOI: 10.1093/Ibd/Izz291 |
0.418 |
|
| 2019 |
Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Alimentary Pharmacology & Therapeutics. PMID 31755121 DOI: 10.1111/Apt.15577 |
0.33 |
|
| 2019 |
Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Peyrin-Biroulet L, Fumery M. Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31743755 DOI: 10.1016/J.Cgh.2019.11.025 |
0.4 |
|
| 2019 |
Hébuterne X, Peyrin-Biroulet L, Hausfater P. The management of emergency hospital visits for inflammatory bowel diseases: A French national expert consensus report. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 31734114 DOI: 10.1016/J.Dld.2019.10.015 |
0.399 |
|
| 2019 |
Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 31732444 DOI: 10.1016/J.Dld.2019.10.003 |
0.345 |
|
| 2019 |
Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis. Gastroenterology. PMID 31711921 DOI: 10.1053/J.Gastro.2019.10.035 |
0.338 |
|
| 2019 |
Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®) for active, mild-to-moderate ulcerative colitis. United European Gastroenterology Journal. 7: 1171-1182. PMID 31700630 DOI: 10.1177/2050640619864848 |
0.357 |
|
| 2019 |
Salem F, Kindt N, Marchesi JR, Netter P, Lopez A, Kokten T, Danese S, Jouzeau JY, Peyrin-Biroulet L, Moulin D. Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. United European Gastroenterology Journal. 7: 1008-1032. PMID 31662859 DOI: 10.1177/2050640619867555 |
0.441 |
|
| 2019 |
Piovani D, Danese S, Peyrin-Biroulet L, Bonovas S. Inflammatory bowel disease: estimates from the global burden of disease 2017 study. Alimentary Pharmacology & Therapeutics. PMID 31660629 DOI: 10.1111/Apt.15542 |
0.431 |
|
| 2019 |
Haghnejad V, Le Berre C, Dominique Y, Zallot C, Guillemin F, Peyrin-Biroulet L. Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 31648920 DOI: 10.1016/J.Dld.2019.09.012 |
0.417 |
|
| 2019 |
Chateau T, Angioi K, Peyrin-Biroulet L. Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn's disease. Journal of Crohn's & Colitis. PMID 31606743 DOI: 10.1093/Ecco-Jcc/Jjz167 |
0.375 |
|
| 2019 |
Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L. Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology. PMID 31593701 DOI: 10.1053/J.Gastro.2019.08.058 |
0.301 |
|
| 2019 |
Chateau T, Le Berre C, Peyrin-Biroulet L. Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases? Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31589974 DOI: 10.1016/J.Cgh.2019.09.036 |
0.408 |
|
| 2019 |
Kotze PG, Peyrin-Biroulet L, Danese S. Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases. Current Drug Targets. 20: 1315-1316. PMID 31556358 DOI: 10.2174/138945012013190902150906 |
0.405 |
|
| 2019 |
Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. The New England Journal of Medicine. 381: 1215-1226. PMID 31553834 DOI: 10.1056/Nejmoa1905725 |
0.425 |
|
| 2019 |
Estevinho MM, Rocha C, Correia L, Lago P, Ministro P, Portela F, Trindade E, Afonso J, Peyrin-Biroulet L, Magro F. Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31526845 DOI: 10.1016/J.Cgh.2019.08.063 |
0.423 |
|
| 2019 |
Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nature Reviews. Gastroenterology & Hepatology. PMID 31520081 DOI: 10.1038/S41575-019-0211-1 |
0.422 |
|
| 2019 |
Piovani D, Danese S, Peyrin-Biroulet L, Bonovas S. Environmental, Nutritional and Socio-Economic Determinants of IBD Incidence: A Global Ecological Study. Journal of Crohn's & Colitis. PMID 31504350 DOI: 10.1093/Ecco-Jcc/Jjz150 |
0.387 |
|
| 2019 |
Le Berre C, Roda G, Nedeljkovic M, Danese S, Peyrin-Biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion On Biological Therapy. PMID 31498003 DOI: 10.1080/14712598.2019.1666101 |
0.392 |
|
| 2019 |
Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Richard D, Pereira B, Goutte M, Buisson A. Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31470175 DOI: 10.1016/J.Cgh.2019.08.041 |
0.434 |
|
| 2019 |
Lawton J, Achit H, Pouillon L, Boschetti E, Demore B, Matton T, Tournier C, Prodel M, Peyrin-Biroulet L, Guillemin F. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience. United European Gastroenterology Journal. 7: 908-913. PMID 31428415 DOI: 10.1177/2050640619853448 |
0.429 |
|
| 2019 |
Ungaro F, Garlatti V, Massimino L, Spinelli A, Carvello M, Sacchi M, Spanò S, Colasante G, Valassina N, Vetrano S, Malesci A, Peyrin-Biroulet L, Danese S, D'Alessio S. mTOR-Dependent Stimulation of Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease. Cells. 8. PMID 31426584 DOI: 10.3390/Cells8080924 |
0.365 |
|
| 2019 |
Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. Expert Review of Gastroenterology & Hepatology. 1-8. PMID 31322440 DOI: 10.1080/17474124.2019.1645595 |
0.392 |
|
| 2019 |
Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative Colitis and Crohn's Disease Have the Same Burden and Goals for Treatment. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31301452 DOI: 10.1016/J.Cgh.2019.07.005 |
0.44 |
|
| 2019 |
D'Haens G, Rieder F, Feagan BG, Higgins PDR, Panes J, Maaser C, Rogler G, Löwenberg M, van der Voort R, Pinzani M, Peyrin-Biroulet L, Danese S. Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. Gastroenterology. PMID 31254502 DOI: 10.1053/J.Gastro.2019.05.072 |
0.44 |
|
| 2019 |
Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ. Approaches to Integrating Biomarkers into Clinical Trials and Care Pathways as Targets for Treatment of Inflammatory Bowel Diseases. Gastroenterology. PMID 31228441 DOI: 10.1053/J.Gastro.2019.06.018 |
0.42 |
|
| 2019 |
Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. PMID 31227590 DOI: 10.1136/Gutjnl-2019-318448 |
0.417 |
|
| 2019 |
D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therapeutic Advances in Gastroenterology. 12: 1756284819848631. PMID 31205486 DOI: 10.1177/1756284819848631 |
0.343 |
|
| 2019 |
Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, ... ... Peyrin-Biroulet L, et al. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31202984 DOI: 10.1016/J.Cgh.2019.05.060 |
0.325 |
|
| 2019 |
Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. The Lancet. Gastroenterology & Hepatology. PMID 31171484 DOI: 10.1016/S2468-1253(19)30173-6 |
0.435 |
|
| 2019 |
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, et al. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Alimentary Pharmacology & Therapeutics. 50: 40-53. PMID 31165509 DOI: 10.1111/apt.15294 |
0.35 |
|
| 2019 |
Argollo MC, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S. Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease? Current Pharmaceutical Design. 25: 25-31. PMID 31092171 DOI: 10.2174/1381612825666190313140811 |
0.342 |
|
| 2019 |
Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L. Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. Journal of Crohn's & Colitis. PMID 31076751 DOI: 10.1093/Ecco-Jcc/Jjz095 |
0.449 |
|
| 2019 |
Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, et al. Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study. Journal of Crohn's & Colitis. PMID 31056693 DOI: 10.1093/Ecco-Jcc/Jjz088 |
0.48 |
|
| 2019 |
Leone D, Gilardi D, Corrò BE, Menichetti J, Vegni E, Correale C, Allocca M, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S, Fiorino G. Psychological Functioning of Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. PMID 31039252 DOI: 10.1093/Ibd/Izz082 |
0.447 |
|
| 2019 |
Fiorino G, Peyrin-Biroulet L, Danese S. Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. Gastroenterology. PMID 31034829 DOI: 10.1053/J.Gastro.2019.04.029 |
0.418 |
|
| 2019 |
Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental Risk Factors for Inflammatory Bowel Diseases: an Umbrella Review of Meta-analyses. Gastroenterology. PMID 31014995 DOI: 10.1053/J.Gastro.2019.04.016 |
0.412 |
|
| 2019 |
Loy L, Roda G, Fiorino G, Allocca M, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S. Detection and management of early stage inflammatory bowel disease: an update for clinicians. Expert Review of Gastroenterology & Hepatology. 1-9. PMID 31007098 DOI: 10.1080/17474124.2019.1605291 |
0.448 |
|
| 2019 |
Allocca M, Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S. Non-invasive Multi-modal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 30995529 DOI: 10.1016/J.Cgh.2019.04.025 |
0.353 |
|
| 2019 |
Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. The American Journal of Gastroenterology. PMID 30908297 DOI: 10.14309/Ajg.0000000000000183 |
0.378 |
|
| 2019 |
Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L, Danese S. Biosimilars of adalimumab in IBD: are we ready for that? Current Pharmaceutical Design. PMID 30864505 DOI: 10.2174/1381612825666190312113610 |
0.408 |
|
| 2019 |
D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy. PMID 30860423 DOI: 10.2217/Imt-2018-0209 |
0.464 |
|
| 2019 |
D'Amico F, Roda G, Peyrin-Biroulet L, Danese S. Anti-adhesion molecules in IBD: does gut specifity really make the difference? Current Pharmaceutical Design. PMID 30848193 DOI: 10.2174/1381612825666190307165703 |
0.401 |
|
| 2019 |
Argollo M, Gilardi D, Roda G, Fiorino G, Peyrin-Biroulet L, Danese S. Anti-fibrotic drugs for Crohn's disease: Ready for prime time? Current Pharmaceutical Design. PMID 30848192 DOI: 10.2174/1381612825666190308100844 |
0.398 |
|
| 2019 |
Le Berre C, Peyrin-Biroulet L, Buisson A, Olympie A, Ravel MH, Bienenfeld C, Gonzalez F. Impact of inflammatory bowel diseases on working life: A French nationwide survey. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 30826278 DOI: 10.1016/J.Dld.2019.01.024 |
0.402 |
|
| 2019 |
Pineton de Chambrun G, Pariente B, Seksik P, Altwegg R, Vuitton L, Stefasnescu C, Nancey S, Aubourg A, Serrero M, Peyrin-Biroulet L, Filippi J, Viennot S, Abitbol V, Boualit M, Boureille A, et al. Adalimumab for patients with Crohn's disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study. Journal of Crohn's & Colitis. 13: S616. PMID 30794285 DOI: 10.1093/Ecco-Jcc/Jjz045 |
0.347 |
|
| 2019 |
Briot C, Faure P, Parmentier AL, Nachury M, Trang C, Viennot S, Altwegg R, Bulois P, Thomassin L, Serrero M, Ah-Soune P, Gilletta C, Plastaras L, Simon M, Dray X, ... ... Peyrin-Biroulet L, et al. Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study. Journal of Crohn's & Colitis. PMID 30785181 DOI: 10.1093/Ecco-Jcc/Jjz040 |
0.389 |
|
| 2019 |
Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Colombel JF, Peyrin-Biroulet L, Kaplan G, Chen MH. Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. Bmj Open. 9: e024222. PMID 30782731 DOI: 10.1136/Bmjopen-2018-024222 |
0.473 |
|
| 2019 |
Danese S, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D, Vavricka S, Halfvarson J, Vermeire S. Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Digestive Diseases (Basel, Switzerland). 1-18. PMID 30726845 DOI: 10.1159/000496739 |
0.414 |
|
| 2019 |
Le Berre C, Danese S, Peyrin-Biroulet L. Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"? Digestive Diseases and Sciences. PMID 30725301 DOI: 10.1007/S10620-019-05504-X |
0.356 |
|
| 2019 |
Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-Biroulet L, Brodmerkel C, De Hertogh G. A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials. Journal of Crohn's & Colitis. PMID 30721964 DOI: 10.1093/Ecco-Jcc/Jjz022 |
0.373 |
|
| 2019 |
Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L. Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. Journal of Crohn's & Colitis. PMID 30698684 DOI: 10.1093/Ecco-Jcc/Jjz029 |
0.329 |
|
| 2019 |
Leone D, Gilardi D, Corrò BE, Menichetti J, Vegni E, Correale C, Mariangela A, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S, Fiorino G. Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflammatory Bowel Diseases. PMID 30689871 DOI: 10.1093/Ibd/Izy400 |
0.44 |
|
| 2019 |
Choukour M, Kivits J, Baker A, Baumann C, Guillemin F, Peyrin-Biroulet L. Personalised medicine in inflammatory bowel diseases: a patient survey. Scandinavian Journal of Gastroenterology. 1. PMID 30663451 DOI: 10.1080/00365521.2018.1555280 |
0.467 |
|
| 2019 |
Olivera P, Danese S, Jay N, Natoli G, Peyrin-Biroulet L. Big data in IBD: a look into the future. Nature Reviews. Gastroenterology & Hepatology. PMID 30659247 DOI: 10.1038/S41575-019-0102-5 |
0.342 |
|
| 2019 |
Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S. Biosimilars of adalimumab: the upcoming challenge in IBD. Expert Opinion On Biological Therapy. PMID 30601098 DOI: 10.1080/14712598.2019.1564033 |
0.393 |
|
| 2019 |
Peyrin-Biroulet L, Feagan B, Pai R, Boruvka A, Oh Y, Scherl A, Scalori A, Arrisi P, Tole S, Rubin D. P069 Correlation Between Histologic Indices and Ulcerative Colitis Activity Measures Among Patients in the HICKORY (Etrolizumab) Open-Label Induction Cohort The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000613244.26833.Fe |
0.313 |
|
| 2019 |
Ghosh S, Sensky T, Casellas F, Kligys K, Petersson J, Peyrin-Biroulet L. 845 Patient and Physician Assessment of Disease Burden in Patients With Early UC: 2-Year Data From ICONIC The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000592916.33515.Be |
0.37 |
|
| 2019 |
Panaccione R, Peyrin-Biroulet L, Danese S, Marano C, O’Brien CD, Szapary P, Zhang H, Johanns J, Leong RWL, Arasaradnam RP, Rowbotham D, Abreu MT, Sands BE. 842 Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results From UNIFI The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000592904.87773.5D |
0.338 |
|
| 2019 |
Peyrin-Biroulet L, Colombel J, Loftus EV, Danese S, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Sands BE, Schreiber S. 757 Histologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000592564.74380.03 |
0.349 |
|
| 2019 |
Limdi JK, Rose A, Noone D, Avedano L, Hayee B, Sturm A, Peyrin-Biroulet L, Finnegan A, Tucknott S, Burisch J, Lobo AJ, Terry H, Fiorino G, Evans J. 743 The Socioeconomic Impact of Living With Ulcerative Colitis: A Burden of Illness Study The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000592508.57927.50 |
0.312 |
|
| 2019 |
Danese S, Loftus EV, Colombel J, Peyrin-Biroulet L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, Sands BE. 716 Early Clinical Response and Remission With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000592400.99617.75 |
0.326 |
|
| 2019 |
Lichtenstein GR, Cohen BL, Salese L, Soonasra A, Modesto I, Wang W, Woodworth DA, Chan G, Quirk D, Su C, Peyrin-Biroulet L. 706 Impact of Baseline Corticosteroid Therapy on Tofacitinib Induction Efficacy and Infection Risk in Patients With Ulcerative Colitis: Data From Global Clinical Trials The American Journal of Gastroenterology. 114. DOI: 10.14309/01.Ajg.0000592360.46252.8A |
0.33 |
|
| 2019 |
Peyrin-Biroulet L, Louis E, Loftus E, Lee W, Cataldi F, Lacerda A, Ghosh S. PWE-047 Improved patient-reported outcomes with upadacitinib over 52 weeks in patients with moderate-to-severe crohn’s disease Gut. 68. DOI: 10.1136/Gutjnl-2019-Bsgabstracts.371 |
0.318 |
|
| 2019 |
Schreiber S, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel J, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Sands BE. OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjz046.001 |
0.301 |
|
| 2019 |
Boschetti G, Pariente B, Laharie D, Roblin X, Gilletta C, Aubourg A, Bourreille A, Zallot C, Hebuterne X, Buisson A, Grimaud J, Bouhnik Y, Allez M, Altwegg R, Viennot S, ... ... Peyrin-Biroulet L, et al. P714 Efficacy and safety of infliximab retreatment in luminal Crohn’s disease: a multi-centre, prospective, observational cohort (REGAIN) study Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.838 |
0.342 |
|
| 2019 |
Venturin C, Nancey S, Roblin X, Peyrin-Biroulet L, Mathieu N, Flourié B, Boschetti G. P618 Vedolizumab acute infusion reactions in inflammatory bowel disease patients: results of a multi-centre retrospective observational cohort study Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.742 |
0.413 |
|
| 2019 |
Dulai P, Peyrin-Biroulet L, Hahn K, Khalife N, Lindner D, Lasch K, Demuth D, Patel H, Jairath V. P537 The impact of early disease control with vedolizumab on surgery rates among patients with Crohn’s disease: a post-hoc analysis of the GEMINI trials Journal of Crohn's and Colitis. 13: S382-S383. DOI: 10.1093/Ecco-Jcc/Jjy222.661 |
0.38 |
|
| 2019 |
Dulai PS, Amiot A, Peyrin-Biroulet L, Singh S, Serrero M, Jairath V, Filippi J, Pariente B, Loftus EV, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, et al. P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.537 |
0.327 |
|
| 2019 |
Peyrin-Biroulet L, Hart A, Kayhan C, Armuzzi A, Schreiber S. P400 Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.524 |
0.32 |
|
| 2019 |
Danese S, Hart A, Dignass A, Fiorino G, Louis E, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L. P380 A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.504 |
0.312 |
|
| 2019 |
Reenaers C, Nachury M, Stefanescu C, Chambrun GPd, Laharie D, Boileve J, Viennot S, Peyrin-Biroulet L, Roblin X, Grimaud J, Bouguen G, Nahon S, Goutorbe F, Coffin B. P286 Bariatric surgery in inflammatory bowel disease: outcome and safety from a GETAID registry population Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.410 |
0.369 |
|
| 2019 |
Bossuyt P, Dreesen E, Rimola J, Devuysere S, Bruecker YD, Vanslembrouck R, Laurent V, Zappa M, Savoye-Collet C, Gils A, Vermeire S, Peyrin-Biroulet L. P265 Pharmacokinetic and pharmacodynamic evaluation of radiological healing in Crohn’s disease patients treated with Infliximab: a TAILORIX MRE substudy Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.389 |
0.396 |
|
| 2019 |
Kirchgesner J, Boschetti G, Buisson A, Yamamoto T, Domenech E, Nancey S, Peyrin-Biroulet L, Uzzan M. P226 Systematic review with meta-analysis of individual data: impact of cut-off values on the performance of faecal calprotectin to detect endoscopic recurrence after intestinal resection in patients with Crohn’s disease Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.350 |
0.357 |
|
| 2019 |
Boube M, Laharie D, Nancey S, Hébuterne X, Fumery M, Pariente B, Roblin X, Peyrin-Biroulet L, Reymond M, Allimant C, Minet-Quinard R, Pereira B, Bommelaer G, Buisson A. P167 The variation of faecal calprotectin level within the first months after bowel resection is predictive of endoscopic postoperative recurrence in patients with Crohn’s disease Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.291 |
0.374 |
|
| 2019 |
Peyrin-Biroulet L, Feagan B, Pai RK, Arulmani U, Boruvka A, Oh YS, Scherl A, Scalori A, Arrisi P, Tole S, Rubin DT. P136 Association between histological indices and ulcerative colitis activity measures among patients in the HICKORY (etrolizumab) open-label induction cohort Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.260 |
0.32 |
|
| 2019 |
Buisson A, Laharie D, Nancey S, Hébuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Goutorbe F, Coban D, Allimant C, Reymond M, Vazeille E, Pereira B, Goutte M, et al. DOP80 Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.114 |
0.412 |
|
| 2019 |
Biron C, Seksik P, Nachury M, Bouhnik Y, Amiot A, Viennot S, Serrero M, Fumery M, Allez M, Siproudhis L, Buisson A, Chambrun GPd, Abitbol, Nancey S, Caillo L, ... ... Peyrin-Biroulet L, et al. DOP74 Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.108 |
0.389 |
|
| 2019 |
Li K, Friedman JR, Marano C, Zhang H, Yang F, Feagan BG, Peyrin-Biroulet L, Hertogh GD. DOP71 Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.105 |
0.305 |
|
| 2019 |
Peyrin-Biroulet L, Danese S, Louis E, Higgins PDR, Dubinsky M, Cataldi F, Zhou Q, Lee W, Kligys K, Lacerda AP. DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.084 |
0.418 |
|
| 2019 |
Van Assche G, Targan SR, Baker T, O’Brien CD, Zhang H, Johanns J, Szapary P, Marano C, Leong RW, Rowbotham D, Hisamatsu T, Danese S, Sands BE, Peyrin-Biroulet L. DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study Journal of Crohn's and Colitis. 13: S054-S055. DOI: 10.1093/Ecco-Jcc/Jjy222.081 |
0.332 |
|
| 2019 |
Yzet C, Ungaro R, Bossuyt P, Baert F, Vanasek T, D'Haens G, Joustra V, Panaccione R, Novacek G, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis S, Hebuterne X, ... ... Peyrin-Biroulet L, et al. Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease : long-term data from CALM Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.032 |
0.404 |
|
| 2019 |
Fumery M, Peyrin-biroulet L, Nancey S, Altwegg R, Veyrard P, Bouguen G, Viennot S, Poullenot F, Filippi J, Buisson A, Bozon A, Gilletta C, Brazier F, Pouillon L, Flourié B, et al. OP24 Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease Journal of Crohns & Colitis. 13. DOI: 10.1093/Ecco-Jcc/Jjy222.023 |
0.308 |
|
| 2019 |
Peyrin-Biroulet L, Panés J, Chiorean M, Zhang J, Vermeire S, Jairath V, Yarur A, Cabell C, Naik S, Sandborn WJ. OP09 Histological remission and mucosal healing in a randomised, placebo-controlled, Phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis Journal of Crohn's and Colitis. 13: S006-S006. DOI: 10.1093/Ecco-Jcc/Jjy222.008 |
0.33 |
|
| 2019 |
Chabot C, Le Berre C, Baumann C, Remen T, De Carvalho Bittencourt M, Danese S, Mercier C, Peyrin-Biroulet L, Bonneton M. Predictors of Flares in Infliximab-treated Children With Inflammatory Bowel Disease Crohn's & Colitis 360. 1. DOI: 10.1093/crocol/otz031 |
0.31 |
|
| 2019 |
Dubinsky M, Panaccione R, Lopez-Sanroman A, Watanabe K, Rubin DT, Peyrin-Biroulet L, Melmed G, Rubin M, Keefer L, Colombel J, Kayhan C. P024 PATIENT AND HEALTHCARE PROVIDER VIEWS ON ULCERATIVE COLITIS TREATMENT GOALS AND QUALITY OF LIFE: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY Gastroenterology. 156: S17-S18. DOI: 10.1053/J.Gastro.2019.01.073 |
0.319 |
|
| 2019 |
Schreiber S, Panaccione R, Kayhan C, Lopez-Sanroman A, Peyrin-Biroulet L, Armuzzi A, Dubinsky M, Melmed G, Rubin M, Connor S, Keefer L, Rubin DT. P023 PATIENT AND HEALTHCARE PROFESSIONAL VIEWS ON EMOTIONAL HEALTH AND INTIMACY IN ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY Gastroenterology. 156: S17. DOI: 10.1053/J.Gastro.2019.01.072 |
0.303 |
|
| 2019 |
Rubin DT, Panaccione R, Kayhan C, Lopez-Sanroman A, Rubin M, Peyrin-Biroulet L, Armuzzi A, Dubinsky M, Keefer L, Melmed G, Colombel J. P006 DISCORDANCE OF COMMUNICATION PRIORITIES BETWEEN HEALTHCARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY Gastroenterology. 156: S6-S7. DOI: 10.1053/J.Gastro.2019.01.053 |
0.33 |
|
| 2019 |
Armuzzi A, Kayhan C, Panaccione R, Watanabe K, Molander P, Rubin DT, Peyrin-Biroulet L, Melmed G, Connor S, Colombel J, Dubinsky M. P005 Delay In Diagnosis Of Ulcerative Colitis: Results Of A Global Ulcerative Colitis Narrative Survey Gastroenterology. 156. DOI: 10.1053/J.Gastro.2019.01.052 |
0.322 |
|
| 2019 |
Bossuyt P, Dreesen E, Rimola J, Vuysere SD, Bruecker YD, Vanslembrouck R, Laurent v, Zappa M, Savoye-Collet C, Gils A, Vermeire S, Peyrin-Biroulet L. Tu1821 – Pharmacokinetic and Pharmacodynamic Evaluation of Radiological Healing in Crohn's Disease Patients Treated with Infliximab: A Tailorix Mre Substudy Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)39807-5 |
0.425 |
|
| 2019 |
Danese S, Hart A, Dignass A, Fiorino G, Louis E, D'Haens GR, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L. Tu1800 – A Prospective Multicenter Observational Cohort Study Assessing the Effectiveness of Budesonide Mmx® for Mildto-Moderate Ulcerative Colitis Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)39786-0 |
0.308 |
|
| 2019 |
Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Pereira B, Goutte M, Buisson A. Tu1748 – Oral Curcumin is Not More Effective Than Placebo to Prevent Endoscopic Postoperative Recurrence in Patients with Crohn's Disease Treated with Concomitant Thiopurines: Results from a Randomized Controlled Trial Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)39734-3 |
0.391 |
|
| 2019 |
Yarur AJ, Jairath V, Zhang J, Panes J, Chiorean MV, Peyrin-Biroulet L, Vermeire S, Cabell C, Naik S, Sandborn WJ. Tu1745 – Correlation of Fecal Calprotectin and C-Reactive Protein Concentrations with Clinical Outcomes and Endoscopic Disease Activity in Patients with Ulcerative Colitis Receiving Induction Therapy with Etrasimod Gastroenterology. 156: S-1108-S-1109. DOI: 10.1016/S0016-5085(19)39731-8 |
0.372 |
|
| 2019 |
Van Assche GA, Targan SR, Baker T, O'Brien CD, Zhang H, Johanns J, Szapary P, Marano CW, Leong RW, Rowbotham D, Hisamatsu T, Danese S, Sands BE, Peyrin-Biroulet L. Tu1740 – Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Maintenance Study Gastroenterology. 156: S-1106-S-1107. DOI: 10.1016/S0016-5085(19)39726-4 |
0.325 |
|
| 2019 |
Li K, Friedman JR, Marano CW, Zhang H, Yang F, Feagan BG, Peyrin-Biroulet L, Hertogh GD. Tu1735 – Effects of Ustekinumab Induction Therapy on Endoscopic and Histologic Healing in the Unifi Phase 3 Study in Ulcerative Colitis Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)39721-5 |
0.302 |
|
| 2019 |
Dulai PS, Peyrin-Biroulet L, Hahn K, Khalife N, Lindner D, Lasch K, Demuth D, Patel H, Jairath V. Tu1726 – The Impact of Early Disease Control with Vedolizumab on Surgery Rates Among Patients with Crohn's Disease: A Post Hoc Analysis of the Gemini Trials Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)39712-4 |
0.397 |
|
| 2019 |
Peyrin-Biroulet L, Danese S, Louis E, Higgins PD, Dubinsky M, Cataldi F, Zhou Q, Lee W, Kligys K. Mo1837 – Effect of Upadacitinib on Extra-Intestinal Manifestations in Patients with Moderate to Severe Crohn’s Disease: Data from the Celest Study Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)39104-8 |
0.405 |
|
| 2019 |
Dulai PS, Amiot A, Peyrin-Biroulet L, Singh S, Serrero M, Jairath V, Filippi J, Pariente B, Loftus EV, Roblin X, Kane SV, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, et al. Mo1800 – A Simple Scoring Tool Predicts Exposure-Response Relationship, Onset of Action, Response to Interval Shortening, and Surgical Risk with Vedolizumab Therapy for Crohn’s Disease Gastroenterology. 156: S-843. DOI: 10.1016/S0016-5085(19)39067-5 |
0.307 |
|
| 2019 |
Ghosh S, Casellas F, O’shea C, Kligys K, Petersson JH, Peyrin-Biroulet L. Sa1875 – Disease-Related Worries and Concerns in Patients with Ulcerative Colitis: 1-Year Data from Iconic Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)37941-7 |
0.404 |
|
| 2019 |
Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Armuzzi A, Golovchenko O, Olga P, Goldis A, Travis SP, Hebuterne X, ... ... Peyrin-Biroulet L, et al. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)37879-5 |
0.4 |
|
| 2019 |
Peyrin-Biroulet L, Panés J, Chiorean MV, Zhang J, Vermeire S, Jairath V, Yarur AJ, Cabell C, Naik S, Sandborn WJ. 1006 – Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis Gastroenterology. 156: S-217. DOI: 10.1016/S0016-5085(19)37338-X |
0.322 |
|
| 2019 |
Sands BE, Sandborn WJ, Peyrin-Biroulet L, Higgins PD, Hirai F, Belin R, Valderas EG, Miller D, Morgan-Cox M, Naegeli AN, Pollack P, Tuttle J, Hibi T. 1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)37335-4 |
0.366 |
|
| 2019 |
Chambrun GPd, Pariente B, Seksik P, Altwegg R, Vuitton L, Stefanescu C, Nancey S, Aubourg A, Serrero M, Peyrin-Biroulet L, Filippi J, Viennot S, Abitbol V, Boualit M, Bourreille A, et al. 569 – Adalimumab for Patients with Crohn's Disease Complicated by Intra-Abdominal Abscess: A Multicenter Prospective, Observational Cohort Study Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)37072-6 |
0.425 |
|
| 2019 |
Boschetti G, Pariente B, Laharie D, Roblin X, Gilletta C, Aubourg A, Bourreille A, Zallot C, Hebuterne X, Buisson A, Grimaud J, Bouhnik Y, Allez M, Altwegg R, Viennot S, ... ... Peyrin-Biroulet L, et al. 365 – Efficacy and Safety of Infliximab Retreatment in Luminal Crohn's Disease: A Multicentre, Prospective, Observational Cohort (Regain) Study Gastroenterology. 156. DOI: 10.1016/S0016-5085(19)36971-9 |
0.372 |
|
| 2019 |
Rahmi G, Coron E, Levy M, Moreau J, Moussata D, Perrod G, Bourreille A, Trang C, Queneherve L, Perrot B, Cellier C, Peyrin-Biroulet L. Tu1995 DEVELOPMENT OF AN ENDOMICROSCOPIC INDEX TO EVALUATE IN VIVO HISTOLOGICAL HEALING IN ULCERATIVE COLITIS PATIENTS: THE ENHANCE INDEX FROM THE FRENCH SOCIETY OF ENDOSCOPY (SFED) Gastrointestinal Endoscopy. 89. DOI: 10.1016/J.Gie.2019.03.1139 |
0.324 |
|
| 2018 |
Peyrin-Biroulet L, Demarest S, Nirula A. Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies. Autoimmunity Reviews. PMID 30572136 DOI: 10.1016/J.Autrev.2018.07.014 |
0.418 |
|
| 2018 |
Olivera P, Danese S, Pouillon L, Bonovas S, Peyrin-Biroulet L. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 30555013 DOI: 10.1016/J.Dld.2018.11.002 |
0.373 |
|
| 2018 |
Pouillon L, Lamoureux A, Pineton de Chambrun G, Vuitton L, Pariente B, Zallot C, Dufour G, Fumery M, Baumann C, Amiot A, Nancey S, Rousseau H, Peyrin-Biroulet L. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 30502230 DOI: 10.1016/J.Dld.2018.10.022 |
0.413 |
|
| 2018 |
Sitte J, Frentiu E, Baumann C, Rousseau H, May T, Bronowicki JP, Peyrin-Biroulet L, Lopez A. Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage. Alimentary Pharmacology & Therapeutics. PMID 30485467 DOI: 10.1111/Apt.15057 |
0.338 |
|
| 2018 |
Pouillon L, Baumann C, Rousseau H, Choukour M, Andrianjafy C, Danese S, Peyrin-Biroulet L. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. Inflammatory Bowel Diseases. PMID 30329067 DOI: 10.1093/Ibd/Izy322 |
0.355 |
|
| 2018 |
Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RW, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intestinal Research. PMID 30321913 DOI: 10.5217/Ir.2018.00073 |
0.353 |
|
| 2018 |
Attar A, Duru G, Roblin X, Savarieau B, Brunel P, Lamure M, Peyrin-Biroulet L. Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 30268737 DOI: 10.1016/J.Dld.2018.08.029 |
0.377 |
|
| 2018 |
Ungaro F, Massimino L, Furfaro F, Rimoldi V, Peyrin-Biroulet L, D'Alessio S, Danese S. Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes. 1-10. PMID 30252582 DOI: 10.1080/19490976.2018.1511664 |
0.426 |
|
| 2018 |
Pellet G, Stefanescu C, Carbonnel F, Peyrin-Biroulet L, Roblin X, Allimant C, Nachury M, Nancey S, Filippi J, Altwegg R, Brixi H, Fotsing G, de Rosamel L, Shili S, Laharie D, et al. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination with Vedolizumab in Patients With Refractory Ulcerative Colitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 30213584 DOI: 10.1016/J.Cgh.2018.08.081 |
0.322 |
|
| 2018 |
Le Baut G, Peyrin-Biroulet L, Bouguen G, Gornet JM, Stefanescu C, Amiot A, Laharie D, Altwegg R, Fumery M, Trang C, Vuitton L, Simon M, Gilletta de Saint Joseph C, Nahon S, Caillo L, et al. Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif (GETAID). Alimentary Pharmacology & Therapeutics. PMID 30194687 DOI: 10.1111/Apt.14946 |
0.427 |
|
| 2018 |
Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, Neurath MF, Hawkey C. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 30120066 DOI: 10.1016/J.Dld.2018.06.010 |
0.321 |
|
| 2018 |
Pouillon L, Socha M, Demore B, Thilly N, Abitbol V, Danese S, Peyrin-Biroulet L. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Review of Clinical Immunology. 1-11. PMID 30118338 DOI: 10.1080/1744666X.2018.1512406 |
0.311 |
|
| 2018 |
Le Berre C, Loeuille D, Peyrin-Biroulet L. Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 30114486 DOI: 10.1016/J.Cgh.2018.08.017 |
0.338 |
|
| 2018 |
Duricova D, Sarter H, Savoye G, Leroyer A, Pariente B, Armengol-Debeir L, Bouguen G, Ley D, Turck D, Templier C, Buche S, Peyrin-Biroulet L, Gower-Rousseau C, Fumery M. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study. Inflammatory Bowel Diseases. PMID 30085159 DOI: 10.1093/Ibd/Izy254 |
0.45 |
|
| 2018 |
Allocca M, Fiorino G, Bonovas S, Furfaro F, Gilardi D, Argollo M, Magnoni P, Peyrin-Biroulet L, Danese S. Accuracy of Humanitas Ultrasound Criteria in assessing disease activity and severity in ulcerative colitis: a prospective study. Journal of Crohn's & Colitis. PMID 30085066 DOI: 10.1093/Ecco-Jcc/Jjy107 |
0.411 |
|
| 2018 |
Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, et al. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. PMID 30076171 DOI: 10.1136/Gutjnl-2018-316702 |
0.373 |
|
| 2018 |
Belle A, Laurent V, Pouillon L, Baumann C, Orry X, Lopez A, Rousseau H, Bronowicki JP, Peyrin-Biroulet L. Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 30076016 DOI: 10.1016/J.Dld.2018.06.024 |
0.414 |
|
| 2018 |
Peyrin-Biroulet L, Lopez A, Cummings JRF, Dignass A, Detlie TE, Danese S. Review article: treating-to-target for inflammatory bowel disease-associated anaemia. Alimentary Pharmacology & Therapeutics. PMID 30069896 DOI: 10.1111/apt.14922 |
0.303 |
|
| 2018 |
Bonovas S, Pantavou K, Evripidou D, Bastiampillai AJ, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. Best Practice & Research. Clinical Gastroenterology. 32: 43-47. PMID 30060938 DOI: 10.1016/J.Bpg.2018.05.005 |
0.323 |
|
| 2018 |
Pouillon L, Van Stappen J, Bossuyt P, Danese S, Peyrin-Biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Practice & Research. Clinical Gastroenterology. 32: 17-25. PMID 30060934 DOI: 10.1016/J.Bpg.2018.05.006 |
0.329 |
|
| 2018 |
Lopez A, Pouillon L, Beaugerie L, Danese S, Peyrin-Biroulet L. Colorectal cancer prevention in patients with ulcerative colitis. Best Practice & Research. Clinical Gastroenterology. 32: 103-109. PMID 30060933 DOI: 10.1016/J.Bpg.2018.05.010 |
0.341 |
|
| 2018 |
Thierry ML, Rousseau H, Pouillon L, Girard-Gavanier M, Baumann C, Lopez A, Danese S, Laurent V, Peyrin-Biroulet L. Accuracy of diffusion-weighted magnetic resonance imaging in detecting mucosal healing and treatment response, and in predicting surgery, in Crohn's disease. Journal of Crohn's & Colitis. PMID 29985999 DOI: 10.1093/Ecco-Jcc/Jjy098 |
0.305 |
|
| 2018 |
Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opinion On Investigational Drugs. 1-7. PMID 29985060 DOI: 10.1080/13543784.2018.1494722 |
0.445 |
|
| 2018 |
Allocca M, Fiorino G, Bonifacio C, Furfaro F, Gilardi D, Argollo M, Peyrin-Biroulet L, Danese S. Comparative accuracy of bowel ultrasound versus magnetic resonance enterography in combination with colonoscopy in assessing Crohn's disease and guiding clinical decision-making. Journal of Crohn's & Colitis. PMID 29982361 DOI: 10.1093/Ecco-Jcc/Jjy093 |
0.343 |
|
| 2018 |
Bonovas S, Peyrin-Biroulet L, Danese S. Meta-analysis of the Association between anti-TNF use and Lymphoma Risk in Patients with Inflammatory bowel Disease: Methodological Considerations. Journal of Crohn's & Colitis. PMID 29947742 DOI: 10.1093/Ecco-Jcc/Jjy094 |
0.433 |
|
| 2018 |
Peyrin-Biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M, Lytras T, Bonovas S. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: a Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 29935327 DOI: 10.1016/J.Cgh.2018.06.026 |
0.404 |
|
| 2018 |
Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. Journal of Gastroenterology. PMID 29869016 DOI: 10.1007/S00535-018-1480-0 |
0.4 |
|
| 2018 |
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, ... ... Peyrin-Biroulet L, et al. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflammatory Bowel Diseases. PMID 29788318 DOI: 10.1093/Ibd/Izy155 |
0.429 |
|
| 2018 |
Pouillon L, Laurent V, Pouillon M, Bossuyt P, Bonifacio C, Danese S, Deepak P, Loftus EV, Bruining DH, Peyrin-Biroulet L. Diffusion-weighted MRI in inflammatory bowel disease. The Lancet. Gastroenterology & Hepatology. 3: 433-443. PMID 29739674 DOI: 10.1016/S2468-1253(18)30054-2 |
0.36 |
|
| 2018 |
Duricova D, Pariente B, Sarter H, Fumery M, Leroyer A, Charpentier C, Armengol-Debeir L, Peyrin-Biroulet L, Savoye G, Gower-Rousseau C. Impact of age at diagnosis on natural history of patients with elderly-onset ulcerative colitis: A French population-based study. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 29739650 DOI: 10.1016/J.Dld.2018.04.011 |
0.371 |
|
| 2018 |
Sacleux SC, Sarter H, Fumery M, Charpentier C, Guillon-Dellac N, Coevoet H, Pariente B, Peyrin-Biroulet L, Gower-Rousseau C, Savoye G. Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. Alimentary Pharmacology & Therapeutics. PMID 29737553 DOI: 10.1111/Apt.14790 |
0.356 |
|
| 2018 |
Roblin X, Vérot C, Paul S, Duru G, Williet N, Boschetti G, Del Tedesco E, Peyrin-Biroulet L, Marc Phelip J, Nancey S, Flourie B. Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF? Inflammatory Bowel Diseases. PMID 29718216 DOI: 10.1093/Ibd/Izy111 |
0.387 |
|
| 2018 |
Danese S, D'Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflammatory Bowel Diseases. PMID 29697791 DOI: 10.1093/Ibd/Izy076 |
0.37 |
|
| 2018 |
Rolli V, Macquin C, Kokten T, Hablot J, Ndiaye NC, Netter P, Bahram S, Jouzeau JY, Peyrin-Biroulet L, Georgel P, Moulin D. Zinc-Alpha-2-Glycoprotein in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 24: e10. PMID 29688476 DOI: 10.1093/Ibd/Izy120 |
0.38 |
|
| 2018 |
Altwegg R, Combes R, Laharie D, De Ledinghen V, Radenne S, Conti F, Chazouilleres O, Duvoux C, Dumortier J, Leroy V, Treton X, Durand F, Dharancy S, Nachury M, Goutorbe F, ... ... Peyrin-Biroulet L, et al. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 29655972 DOI: 10.1016/J.Dld.2018.02.014 |
0.381 |
|
| 2018 |
Bonovas S, Peyrin-Biroulet L, Danese S. Infliximab biosimilar CT-P13 for inflammatory bowel disease. The Lancet. Gastroenterology & Hepatology. PMID 29606565 DOI: 10.1016/S2468-1253(18)30116-X |
0.384 |
|
| 2018 |
Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L. Identification of Endpoints for Development of Anti-fibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. PMID 29601825 DOI: 10.1053/J.Gastro.2018.03.032 |
0.45 |
|
| 2018 |
Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, et al. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 29596987 DOI: 10.1016/J.Cgh.2018.02.051 |
0.345 |
|
| 2018 |
Shafer LA, Walker JR, Chhibba T, Ivekovic M, Singh H, Targownik LE, Peyrin-Biroulet L, Gower-Rousseau C, Sarter H, Bernstein CN. Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients. Inflammatory Bowel Diseases. PMID 29554260 DOI: 10.1016/S0016-5085(17)30455-9 |
0.349 |
|
| 2018 |
Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M. Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. United European Gastroenterology Journal. 6: 310-321. PMID 29511561 DOI: 10.1177/2050640617708952 |
0.353 |
|
| 2018 |
Argollo M, Fiorino G, Peyrin-Biroulet L, Danese S. Vedolizumab for the treatment of Crohn's disease. Expert Review of Clinical Immunology. PMID 29406811 DOI: 10.1080/1744666X.2018.1438189 |
0.426 |
|
| 2018 |
Jaboli F, Pouillon L, Bossuyt P, Danese S, Peyrin-Biroulet L. Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach! Gastroenterology. PMID 29391131 DOI: 10.1053/J.Gastro.2018.01.036 |
0.473 |
|
| 2018 |
Yacoub W, Williet N, Pouillon L, Di-Bernado T, De Carvalho Bittencourt M, Nancey S, Lopez A, Paul S, Zallot C, Roblin X, Peyrin-Biroulet L. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Alimentary Pharmacology & Therapeutics. PMID 29384209 DOI: 10.1111/Apt.14548 |
0.391 |
|
| 2018 |
Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 29371056 DOI: 10.1016/J.Dld.2017.12.027 |
0.408 |
|
| 2018 |
Allocca M, Gilardi D, Fiorino G, Furfaro F, Peyrin-Biroulet L, Danese S. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. European Journal of Gastroenterology & Hepatology. PMID 29351114 DOI: 10.1097/Meg.0000000000001074 |
0.316 |
|
| 2018 |
Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L. Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Alimentary Pharmacology & Therapeutics. 47: 773-783. PMID 29349829 DOI: 10.1111/Apt.14514 |
0.439 |
|
| 2018 |
Gouynou C, Pouillon L, Rousseau H, Zallot C, Baumann C, Peyrin-Biroulet L. Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation. Gut. PMID 29331941 DOI: 10.1136/Gutjnl-2017-315766 |
0.417 |
|
| 2018 |
D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, ... ... Peyrin-Biroulet L, et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. PMID 29317275 DOI: 10.1053/J.Gastro.2018.01.004 |
0.36 |
|
| 2018 |
Dulai PS, Jairath V, Wright D, Calleja A, Demuth D, Campbell-Hill S, Peyrin-Biroulet L. Assessment of Biologic Treatment Outcomes in Inflammatory Bowel Disease Patients with ‘Early Diseaseʼ: Results of a Systematic Literature Review: 584 The American Journal of Gastroenterology. 113. DOI: 10.14309/00000434-201810001-00584 |
0.404 |
|
| 2018 |
Haaren Sv, Ghosh S, Peyrin-Biroulet L, Casellas F, O’Shea C, Lee W, Pappalardo B, Petersson J. PWE-067 Healthcare resource utilisation and QOL in patients with UC by disease severity: iconic baseline data Gut. 67. DOI: 10.1136/Gutjnl-2018-Bsgabstracts.199 |
0.308 |
|
| 2018 |
Duricová D, Sarter H, Savoye G, Leroyer A, Pariente B, Armengol-Debeir L, Bouguen G, Ley D, Turck D, Templier C, Buche S, Peyrin-Biroulet L, Gower-Rousseau C, Fumery M. P822 Impact of extra-intestinal manifestations at diagnosis on disease outcome in paediatric- and elderly-onset Crohn′s Disease: A French population-based study Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.949 |
0.378 |
|
| 2018 |
Bendaoud S, Nahon S, Gornet JM, Pariente B, Beaugerie L, Abitbol V, Peyrin-Biroulet L, Buisson A, Hebuterne X, Altwegg R, Amil M, Rosa I, Heluwaert F, Plastaras L, Antony M, et al. P817 Live-vaccines and lactation in newborn exposed in utero to anti-TNF: A multi-centre French experience in inflammatory bowel disease Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.944 |
0.368 |
|
| 2018 |
Gonzalez F, Buisson A, Olympie A, Ravel MH, Bienenfeld C, Peyrin-Biroulet L. P787 Impact of inflammatory bowel disease on working life: A French nationwide survey Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.914 |
0.39 |
|
| 2018 |
Chambrun GPd, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Bouhnik Y, Laharie D, Seksik P, ... ... Peyrin-Biroulet L, et al. P728 Efficacy of anti-TNF treatment in patients with refractory ulcerative proctitis: Results from a French retrospective multi-centre national cohort Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.855 |
0.362 |
|
| 2018 |
Lambin T, Amiot A, Gornet JM, Seksik P, Laharie D, Louis E, Giletta C, Filippi J, Fumery M, Cadiot G, Chambrun GPd, Nahon S, Serrero M, Coffin B, Plastaras L, ... ... Peyrin-Biroulet L, et al. P458 Long-term outcome of Crohn’s disease complicated by upper gastrointestinal stricture: A GETAID cohort study Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.585 |
0.337 |
|
| 2018 |
Dufour G, Pariente B, Amiot A, Viennot S, Zerbib F, Caillo L, Nancey S, Pouderoux P, Poullenot F, Altwegg R, Peyrin-Biroulet L, Nachury M, Blanc P, Chambrun GPd. P455 Spacing of infliximab infusions over 8 weeks in patients with inflammatory bowel diseases in clinical remission: Final results of a retrospective multicentre French national cohort Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.582 |
0.437 |
|
| 2018 |
Yacoub W, Williet N, Pouillon L, Di-Bernado T, De Carvalho Bittencourt M, Nancey S, Lopez A, Paul S, Zallot C, Roblin X, Peyrin-Biroulet L. P454 Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease Journal of Crohn's and Colitis. 12: S334-S334. DOI: 10.1093/Ecco-Jcc/Jjx180.581 |
0.406 |
|
| 2018 |
Gouynou C, Pouillon L, Rousseau H, Zallot C, Baumann C, Peyrin-Biroulet L. P440 Early changes in the pharmacokinetic profile of vedolizumab-treated patients with inflammatory bowel disease may predict response after dose optimisation Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.567 |
0.4 |
|
| 2018 |
Allocca M, Fiorino G, Furfaro F, Radice S, Gilardi D, Peyrin-Biroulet L, Danese S. P351 Bowel ultrasound is accurate in assessing disease activity in ulcerative colitis Journal of Crohn's and Colitis. 12: S280-S281. DOI: 10.1093/Ecco-Jcc/Jjx180.478 |
0.403 |
|
| 2018 |
Caron B, Peyrin-Biroulet L, Nachury M, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Boureille A, Nancey S, Filippi J, et al. P347 Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.474 |
0.432 |
|
| 2018 |
Buisson A, Fumery M, Hébuterne X, Pariente B, Nancey S, Quinard RM, Peyrin-Biroulet L, Seksik P, Allez M, Lambert C, Dupas JL, Filippi J, Nachury M, Boschetti G, Goutte M, et al. P144 Comparison between faecal chitinase 3-like 1, matrix metalloprotease 9, and calprotectin to assess mucosal healing in Crohn’s disease: a multicentre prospective study Journal of Crohns & Colitis. 12. DOI: 10.1093/Ecco-Jcc/Jjx180.271 |
0.334 |
|
| 2018 |
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen PR, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Bar-Gil Shitrit A, Ardizzone S, Molander P, ... ... Peyrin-Biroulet L, et al. DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study Journal of Crohn's and Colitis. 12: S029-S030. DOI: 10.1093/Ecco-Jcc/Jjx180.038 |
0.45 |
|
| 2018 |
Schreiber S, Dignass A, Peyrin-Biroulet L, Mosli M, Hather G, Demuth D, Blake A, Curtis R, Khalid JM, Loftus EV. P155 Real-World Safety Of Vedolizumab In Inflammatory Bowel Disease: A Meta-Analysis Gastroenterology. 154. DOI: 10.1053/J.Gastro.2017.11.205 |
0.411 |
|
| 2018 |
Peyrin-Biroulet L, Rubin DT, Feagan B, Oh YS, Arulmani U, Tyrrell H, Maciuca R, Williams S, Tole S, Thommes J. 20 ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT Gastroenterology. 154: S17-S18. DOI: 10.1053/J.Gastro.2017.11.070 |
0.373 |
|
| 2018 |
Rubin DT, Feagan BG, Peyrin-Biroulet L, Pai RK, Oh YS, Arulmani U, Boruvka A, Scherl A, Tyrrell H, Tole S. Tu2006 - Etrolizumab Induction Therapy Improves Histologic Outcomes in Anti-TNF-Failed Patients with Ulcerative Colitis: Results from the Hickory Open-Label Induction Cohort Gastroenterology. 154: S-1366. DOI: 10.1016/S0016-5085(18)34465-2 |
0.351 |
|
| 2018 |
Lambin T, Amiot A, Gornet J, Seksik P, Laharie D, Louis E, Gilletta C, Filippi J, Fumery M, Cadiot G, Chambrun GPd, Nahon S, Serrero M, Coffin B, Plastaras L, ... ... Peyrin-Biroulet L, et al. Mo1785 - Long-Term Outcome of Crohn's Disease Complicated by Upper Gastrointestinal Stricture: A Getaid Cohort Study Gastroenterology. 154. DOI: 10.1016/S0016-5085(18)32749-5 |
0.368 |
|
| 2018 |
Buisson A, Fumery M, Hebuterne X, Pariente B, Nancey S, Minet-Quinard R, Peyrin-Biroulet L, Seksik P, Allez M, Lambert C, Dupas J, Filippi J, Nachury M, Boschetti G, Goutte M, et al. Su1798 - Comparison Between Faecal Chitinase 3-Like 1, Matrix Metalloprotease 9 and Calprotectin to Assess Mucosal Healing in Patients with Crohn's Disease: A Multicenter Prospective Study Gastroenterology. 154. DOI: 10.1016/S0016-5085(18)32144-9 |
0.397 |
|
| 2018 |
Allocca M, Fiorino G, Furfaro F, Radice S, Gilardi D, Peyrin-Biroulet L, Danese S. Sa1780 - Bowel Ultrasound is Accurate in Assessing Disease Activity in Ulcerative Colitis Gastroenterology. 154: S-391-S-392. DOI: 10.1016/S0016-5085(18)31604-4 |
0.415 |
|
| 2017 |
Pouillon L, Peyrin-Biroulet L. It is time to revise the STRIDE guidelines determining therapeutic goals for treat-to-target in inflammatory bowel disease. Journal of Crohn's & Colitis. PMID 29309565 DOI: 10.1093/Ecco-Jcc/Jjx174 |
0.414 |
|
| 2017 |
de Boer NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, Colombel JF, Lopez A, Beaugerie L, Marinaki AM, van Bodegraven AA, Neurath MF. Thiopurines in Inflammatory Bowel Disease: new findings and perspectives. Journal of Crohn's & Colitis. PMID 29293971 DOI: 10.1093/Ecco-Jcc/Jjx181 |
0.466 |
|
| 2017 |
Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabate JM, Peyrin-Biroulet L, Colombel JF, Allez M, Fléjou JF, Kirchgesner J, Svrcek M. High risk of anal and rectal cancer in patients with anal and/or perianal Crohn's disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 29199142 DOI: 10.1016/J.Cgh.2017.11.041 |
0.366 |
|
| 2017 |
Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Alimentary Pharmacology & Therapeutics. PMID 29159817 DOI: 10.1111/Apt.14420 |
0.453 |
|
| 2017 |
Allen PB, Gower-Rousseau C, Danese S, Peyrin-Biroulet L. Preventing disability in inflammatory bowel disease. Therapeutic Advances in Gastroenterology. 10: 865-876. PMID 29147137 DOI: 10.1177/1756283X17732720 |
0.41 |
|
| 2017 |
Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. British Journal of Clinical Pharmacology. PMID 29057539 DOI: 10.1111/Bcp.13456 |
0.38 |
|
| 2017 |
Lo B, Prosberg MV, Gluud LL, Chan W, Leong RW, van der List E, van der Have M, Sarter H, Gower-Rousseau C, Peyrin-Biroulet L, Vind I, Burisch J. Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. Alimentary Pharmacology & Therapeutics. PMID 28994131 DOI: 10.1111/Apt.14373 |
0.481 |
|
| 2017 |
Duricova D, Leroyer A, Savoye G, Sarter H, Pariente B, Aoucheta D, Armengol-Debeir L, Ley D, Turck D, Peyrin-Biroulet L, Gower-Rousseau C, Fumery M. Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. Journal of Crohn's & Colitis. PMID 28981648 DOI: 10.1093/Ecco-Jcc/Jjx092 |
0.406 |
|
| 2017 |
Rivière P, Zallot C, Desobry P, Sabaté JM, Vergniol J, Zerbib F, Peyrin-Biroulet L, Laharie D, Poullenot F. Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease. Journal of Crohn's & Colitis. 11: 1347-1352. PMID 28981625 DOI: 10.1093/Ecco-Jcc/Jjx100 |
0.4 |
|
| 2017 |
Kökten T, Gibot S, Lepage P, D'Alessio S, Hablot J, Ndiaye NC, Busby-Venner H, Monot C, Garnier B, Moulin D, Jouzeau JY, Hansmannel F, Danese S, Guéant JL, Muller S, ... Peyrin-Biroulet L, et al. TREM-1 inhibition restores impaired autophagy activity and reduces colitis in mice. Journal of Crohn's & Colitis. PMID 28961797 DOI: 10.1093/Ecco-Jcc/Jjx129 |
0.536 |
|
| 2017 |
Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. Inflammatory Bowel Diseases. PMID 28945636 DOI: 10.1097/Mib.0000000000001223 |
0.365 |
|
| 2017 |
Qiu Y, Chen BL, Feng R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Peyrin-Biroulet L, Mao R, Chen MH. Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. Journal of Gastroenterology and Hepatology. PMID 28940780 DOI: 10.1111/Jgh.14000 |
0.411 |
|
| 2017 |
Hablot J, Peyrin-Biroulet L, Kokten T, El Omar R, Netter P, Bastien C, Jouzeau JY, Sokol H, Moulin D. Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice. Plos One. 12: e0184624. PMID 28926599 DOI: 10.1371/Journal.Pone.0184624 |
0.336 |
|
| 2017 |
Allocca M, Landi R, Bonovas S, Fiorino G, Papa A, Spinelli A, Furfaro F, Peyrin-Biroulet L, Armuzzi A, Danese S. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 96: 166-172. PMID 28903094 DOI: 10.1159/000480231 |
0.389 |
|
| 2017 |
Bossuyt P, Pouillon L, Bonnaud G, Danese S, Peyrin-Biroulet L. E-health in inflammatory bowel diseases: More challenges than opportunities? Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 28899622 DOI: 10.1016/J.Dld.2017.08.026 |
0.386 |
|
| 2017 |
Pouillon L, Bossuyt P, Vanderstukken J, Moulin D, Netter P, Danese S, Jouzeau JY, Loeuille D, Peyrin-Biroulet L. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Review of Clinical Pharmacology. PMID 28879780 DOI: 10.1080/17512433.2017.1377609 |
0.442 |
|
| 2017 |
Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn's disease: towards disease modification trials. Gut. PMID 28874419 DOI: 10.1136/Gutjnl-2017-314519 |
0.457 |
|
| 2017 |
Martelli L, Lopez A, Strobel S, Danese S, Roblin X, Baumann C, Peyrin-Biroulet L. Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. Journal of Digestive Diseases. PMID 28858439 DOI: 10.1111/1751-2980.12539 |
0.429 |
|
| 2017 |
Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 28826571 DOI: 10.1016/J.Dld.2017.07.010 |
0.463 |
|
| 2017 |
Maréchal C, Aimone-Gastin I, Baumann C, Dirrenberger B, Guéant JL, Peyrin-Biroulet L. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United European Gastroenterology Journal. 5: 702-707. PMID 28815034 DOI: 10.1177/2050640616686517 |
0.77 |
|
| 2017 |
Ghione S, Sarter H, Fumery M, Armengol-Debeir L, Savoye G, Ley D, Spyckerelle C, Pariente B, Peyrin-Biroulet L, Turck D, Gower-Rousseau C. Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents. The American Journal of Gastroenterology. PMID 28809388 DOI: 10.1038/Ajg.2017.228 |
0.414 |
|
| 2017 |
Argollo M, Fiorino G, Hindryck P, Peyrin-Biroulet L, Danese S. Novel therapeutic targets for inflammatory bowel disease. Journal of Autoimmunity. PMID 28711286 DOI: 10.1016/J.Jaut.2017.07.004 |
0.425 |
|
| 2017 |
Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, Danese S. Infection risk with biologic therapy in patients with inflammatory bowel disease. Clinical Pharmacology and Therapeutics. PMID 28699217 DOI: 10.1002/Cpt.791 |
0.447 |
|
| 2017 |
Danese S, Fiorino G, Peyrin-Biroulet L. Filgotinib in Crohn Disease: JAK Is Back. Gastroenterology. PMID 28655509 DOI: 10.1053/J.Gastro.2017.06.040 |
0.42 |
|
| 2017 |
Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 28625817 DOI: 10.1016/J.Cgh.2017.06.016 |
0.313 |
|
| 2017 |
Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. International Journal of Molecular Sciences. 18. PMID 28617319 DOI: 10.3390/Ijms18061276 |
0.436 |
|
| 2017 |
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Alimentary Pharmacology & Therapeutics. 46: 310-321. PMID 28593685 DOI: 10.1111/Apt.14167 |
0.412 |
|
| 2017 |
Danese S, Bonovas S, Peyrin-Biroulet L. Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice. Journal of Crohn's & Colitis. PMID 28575273 DOI: 10.1093/Ecco-Jcc/Jjx079 |
0.396 |
|
| 2017 |
Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G, Mathieu S, Thevenin A, Duruy M, Filippi J, Lʼhopital F, ... ... Peyrin-Biroulet L, et al. Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. PMID 28570431 DOI: 10.1097/Mib.0000000000001140 |
0.467 |
|
| 2017 |
Yadav P, Ellinghaus D, Rémy G, Freitag-Wolf S, Cesaro A, Degenhardt F, Boucher G, Delacre M, Peyrin-Biroulet L, Pichavant M, Rioux JD, Gosset P, Franke A, Schumm LP, et al. Genetic Factors Interact With Tobacco Smoke to Modify Risk for Inflammatory Bowel Disease in Humans and Mice. Gastroenterology. PMID 28506689 DOI: 10.1053/J.Gastro.2017.05.010 |
0.343 |
|
| 2017 |
Olivera P, Spinelli A, Gower-Rousseau C, Danese S, Peyrin-Biroulet L. Surgical rates in the era of biological therapy: up, down or unchanged? Current Opinion in Gastroenterology. PMID 28463854 DOI: 10.1097/Mog.0000000000000361 |
0.373 |
|
| 2017 |
Dirrenberger B, Clerc-Urmès I, Germain A, Bresler L, Olivera P, Martelli L, Danese S, Baumann C, Laurent V, Peyrin-Biroulet L. Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 28454853 DOI: 10.1016/J.Dld.2017.03.028 |
0.624 |
|
| 2017 |
Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, Phelip JM, Peyrin-Biroulet L, Colombel JF, Del Tedesco E, Paul S, Flourie B. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Alimentary Pharmacology & Therapeutics. PMID 28449228 DOI: 10.1111/Apt.14106 |
0.457 |
|
| 2017 |
Rencz F, Gulácsi L, Péntek M, Gecse KB, Dignass A, Halfvarson J, Gomollón F, Baji P, Peyrin-Biroulet L, Lakatos PL, Brodszky V. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert Review of Pharmacoeconomics & Outcomes Research. PMID 28434387 DOI: 10.1080/14737167.2017.1322509 |
0.346 |
|
| 2017 |
Bonovas S, Peyrin-Biroulet L, Danese S. Is Mesalamine Effective for the Induction of Remission in Crohn's Disease? Inflammatory Bowel Diseases. 23: E22-E23. PMID 28426460 DOI: 10.1097/Mib.0000000000001124 |
0.419 |
|
| 2017 |
Gulacsi L, Pentek M, Rencz F, Brodszky V, Baji P, Vegh Z, Gecse KB, Danese S, Peyrin-Biroulet L, Lakatos PL. Biosimilars for the management of inflammatory bowel diseases: economic considerations. Current Medicinal Chemistry. PMID 28393687 DOI: 10.2174/0929867324666170406112304 |
0.432 |
|
| 2017 |
Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflammatory Bowel Diseases. PMID 28333755 DOI: 10.1097/Mib.0000000000001072 |
0.394 |
|
| 2017 |
Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Alimentary Pharmacology & Therapeutics. 45: 1291-1302. PMID 28326566 DOI: 10.1111/Apt.14030 |
0.432 |
|
| 2017 |
Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmunity Reviews. PMID 28279838 DOI: 10.1016/J.Autrev.2017.03.007 |
0.363 |
|
| 2017 |
Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Alimentary Pharmacology & Therapeutics. PMID 28247573 DOI: 10.1111/Apt.13995 |
0.399 |
|
| 2017 |
Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. Autoimmunity Reviews. PMID 28212924 DOI: 10.1016/J.Autrev.2017.02.013 |
0.436 |
|
| 2017 |
Attar A, Branche J, Coron E, Privat J, Caillo L, Chevaux JB, Vuitton L, Amiot A, Belkhodja H, Buisson A, Dray X, Jerber L, Ponchon T, Bouhnik Y, Peyrin-Biroulet L. P608 New anti-migration extractible metal stents for Crohn's disease strictures: a nationwide GETAID-SFED cohort study. Journal of Crohn's & Colitis. 11: S389-S390. PMID 28175172 DOI: 10.1093/Ecco-Jcc/Jjx002.732 |
0.341 |
|
| 2017 |
Allocca M, Fiorino G, Bonifacio C, Furfaro F, Radice S, Gilardi D, Peyrin-Biroulet L, Danese S. P277 Comparative accuracy of US versus MRI and colonoscopy in assessing disease activity and complications and influencing the decision-making process in Crohn's disease. Journal of Crohn's & Colitis. 11: S218-S219. PMID 28175059 DOI: 10.1016/S0016-5085(17)30574-7 |
0.374 |
|
| 2017 |
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Serrero M, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, et al. DOP027 Long-term efficacy and safety of ustekinumab in refractory Crohn's disease patients: a multicenter retrospective experience. Journal of Crohn's & Colitis. 11: S43. PMID 28174927 DOI: 10.1093/Ecco-Jcc/Jjx002.064 |
0.37 |
|
| 2017 |
Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Review of Clinical Immunology. PMID 28164724 DOI: 10.1080/1744666X.2017.1291342 |
0.428 |
|
| 2017 |
Ghosh S, Louis E, Beaugerie L, Bossuyt P, Bouguen G, Bourreille A, Ferrante M, Franchimont D, Frost K, Hebuterne X, Marshall JK, OʼShea C, Rosenfeld G, Williams C, Peyrin-Biroulet L. Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. PMID 28146002 DOI: 10.1097/Mib.0000000000001033 |
0.396 |
|
| 2017 |
Bouhnik Y, Carbonnel F, Laharie D, Stefanescu C, Hébuterne X, Abitbol V, Nachury M, Brixi H, Bourreille A, Picon L, Bourrier A, Allez M, Peyrin-Biroulet L, Moreau J, Savoye G, et al. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. PMID 28119352 DOI: 10.1136/Gutjnl-2016-312581 |
0.422 |
|
| 2017 |
Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Alimentary Pharmacology & Therapeutics. PMID 28112419 DOI: 10.1111/Apt.13948 |
0.326 |
|
| 2017 |
Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease. Inflammatory Bowel Diseases. 23: 126-132. PMID 28002129 DOI: 10.1097/Mib.0000000000000986 |
0.364 |
|
| 2017 |
Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 66: 199-209. PMID 27856614 DOI: 10.1136/Gutjnl-2016-312912 |
0.375 |
|
| 2017 |
Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. Journal of Gastroenterology. 52: 19-25. PMID 27665099 DOI: 10.1007/S00535-016-1266-1 |
0.334 |
|
| 2017 |
Williet N, Sarter H, Gower-Rousseau C, Adrianjafy C, Olympie A, Buisson A, Beaugerie L, Peyrin-Biroulet L. Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients. Journal of Crohn's & Colitis. 11: 165-174. PMID 27516406 DOI: 10.1093/Ecco-Jcc/Jjw145 |
0.44 |
|
| 2017 |
Peyrin-Biroulet L, Lönnfors S, Roblin X, Danese S, Avedano L. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. Journal of Crohn's & Colitis. 11: 128-133. PMID 27481878 DOI: 10.1093/Ecco-Jcc/Jjw138 |
0.364 |
|
| 2017 |
Guinet-Charpentier C, Lepage P, Morali A, Chamaillard M, Peyrin-Biroulet L. Effects of enteral polymeric diet on gut microbiota in children with Crohn's disease. Gut. 66: 194-195. PMID 26818618 DOI: 10.1136/Gutjnl-2015-311058 |
0.328 |
|
| 2017 |
Dubinsky MC, Peyrin-Biroulet L, Melmed GY, Hou JK, Woodworth DA, Friedman GS, Zhang H, Maller E, Quirk D, Nduaka CI, Su C. Efficacy of Tofacitinib in Patients With Ulcerative Colitis by Prior Tumor Necrosis Factor Inhibitor Treatment Status: Results From OCTAVE Induction and Maintenance Studies: 640 The American Journal of Gastroenterology. 112. DOI: 10.14309/00000434-201710001-00640 |
0.318 |
|
| 2017 |
Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis Alimentary Pharmacology & Therapeutics. 47: 454-465. DOI: 10.1111/Apt.14449 |
0.329 |
|
| 2017 |
Dirrenberger B, Clerc-Urmès I, Germain A, Bresler L, Olivera P, Martelli L, Baumann C, Laurent V, Peyrin-Biroulet L. P338 Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal Journal of Crohns & Colitis. 11. DOI: 10.1093/Ecco-Jcc/Jjx002.463 |
0.61 |
|
| 2017 |
Danese S, Gisbert J, Lobo A, Dignass A, Peyrin-Biroulet L, Kokot M, Avedano L. P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey Journal of Crohn's and Colitis. 11: S244-S244. DOI: 10.1093/Ecco-Jcc/Jjx002.453 |
0.372 |
|
| 2017 |
Sacleux S, Charpentier C, Sarter H, Fumery M, Guillon-Dellac N, Laberenne E, Pariente B, Peyrin-biroulet L, Gower-Rousseau C, Savoye G. DOP045 Post-operative complications in elderly-onset inflammatory bowel disease: a population-based study Journal of Crohn's and Colitis. 11: S53-S53. DOI: 10.1093/Ecco-Jcc/Jjx002.082 |
0.388 |
|
| 2017 |
Tadbiri S, Grimaud J, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, et al. DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID Journal of Crohn's and Colitis. 11: S42-S42. DOI: 10.1093/Ecco-Jcc/Jjx002.062 |
0.478 |
|
| 2017 |
Travis SP, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Thakkar RB, Pappalardo B, Petersson JH, Bereswill M, Chen N, Skup M. Effect of Adalimumab on Extraintestinal Manifestations Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada Gastroenterology. 152: S743. DOI: 10.1016/S0016-5085(17)32581-7 |
0.323 |
|
| 2017 |
Ghosh S, Peyrin-Biroulet L, Sensky T, Casellas F, O'Shea C, Pappalardo B. Correlation between Physician and Patient Disease Assessments in Ulcerative Colitis: Baseline Data from the Iconic Study of 1816 Patients in 33 Countries Gastroenterology. 152: S741. DOI: 10.1016/S0016-5085(17)32576-3 |
0.383 |
|
| 2017 |
Peyrin-Biroulet L, Feagan B, Mansfield J, Rubin D, Arulmani U, Maciuca R, Tyrrell H, Thommes J, Tole S. OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study Journal of Crohn's and Colitis. 11: S6-S7. DOI: 10.1016/S0016-5085(17)32152-2 |
0.341 |
|
| 2017 |
Tadbiri S, Grimaud J, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang C, Altwegg R, Marteau PR, Vaysse T, Bourrier A, Laharie D, Allez M, et al. Efficacy of Vedolizumab on Extraintestinal Manifestation in Patients with Inflammatory Bowel Diseases: A Post-Hoc Analysis of the Observ-IBD Cohort of the Getaid Gastroenterology. 152. DOI: 10.1016/S0016-5085(17)31562-7 |
0.478 |
|
| 2017 |
Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Khalid J, Loftus E. P466 Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis Journal of Crohn's and Colitis. 11: S315-S315. DOI: 10.1016/S0016-5085(17)31395-1 |
0.417 |
|
| 2017 |
Rivière P, Zallot C, Desobry P, Sabaté J, Vergniol J, Zerbib F, Peyrin-Biroulet L, Laharie D, Poullenot F. P499 Sexual dysfunction is frequent among inflammatory bowel disease patients: results of a prospective study Journal of Crohn's and Colitis. 11: S332-S333. DOI: 10.1016/S0016-5085(17)30792-8 |
0.397 |
|
| 2016 |
Bequet E, Sarter H, Fumery M, Vasseur F, Armengol-Debeir L, Pariente B, Ley D, Spyckerelle C, Coevoet H, Laberenne J, Peyrin-Biroulet L, Savoye G, Turck D, Gower-Rousseau C. Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011]. Journal of Crohns & Colitis. 11: 519-526. PMID 28453757 DOI: 10.1093/Ecco-Jcc/Jjw194 |
0.424 |
|
| 2016 |
Mallet AL, Bouguen G, Conroy G, Roblin X, Delobel JB, Bretagne JF, Siproudhis L, Peyrin-Biroulet L. Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 28089625 DOI: 10.1016/J.Dld.2016.12.001 |
0.311 |
|
| 2016 |
Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X. French national consensus clinical guidelines for the management of Crohn's disease. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 28087156 DOI: 10.1016/J.Dld.2016.12.008 |
0.356 |
|
| 2016 |
Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. PMID 27995656 DOI: 10.1111/Apt.13897 |
0.385 |
|
| 2016 |
Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J, Peyrin-Biroulet L. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. Journal of Crohn's & Colitis. PMID 27927718 DOI: 10.1093/Ecco-Jcc/Jjw198 |
0.362 |
|
| 2016 |
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet (London, England). PMID 27914655 DOI: 10.1016/S0140-6736(16)31711-1 |
0.425 |
|
| 2016 |
Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Alimentary Pharmacology & Therapeutics. PMID 27883215 DOI: 10.1111/apt.13838 |
0.357 |
|
| 2016 |
Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Alimentary Pharmacology & Therapeutics. PMID 27862107 DOI: 10.1111/Apt.13847 |
0.439 |
|
| 2016 |
Michetti P, Weinman J, Mrowietz U, Smolen J, Peyrin-Biroulet L, Louis E, Schremmer D, Tundia N, Nurwakagari P, Selenko-Gebauer N. Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. Advances in Therapy. PMID 27854054 DOI: 10.1007/S12325-016-0441-3 |
0.317 |
|
| 2016 |
Fiorino G, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, Laurent V, Zallot C, Peyrin-Biroulet L, Danese S. Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. Journal of Crohn's & Colitis. PMID 27799269 DOI: 10.1093/Ecco-Jcc/Jjw185 |
0.659 |
|
| 2016 |
Siegel CA, Whitman CB, Spiegel BM, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, ... ... Peyrin-Biroulet L, et al. Development of an index to define overall disease severity in IBD. Gut. PMID 27780886 DOI: 10.1136/Gutjnl-2016-312648 |
0.392 |
|
| 2016 |
Martelli L, Peyrin-Biroulet L. Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: A systematic review. Current Medicinal Chemistry. PMID 27758715 DOI: 10.2174/0929867323666161014153346 |
0.344 |
|
| 2016 |
Duricova D, Fumery M, Annese V, Lakatos PL, Peyrin-Biroulet L, Gower-Rousseau C. The natural history of Crohn's disease in children: a review of population-based studies. European Journal of Gastroenterology & Hepatology. PMID 27748673 DOI: 10.1097/Meg.0000000000000761 |
0.345 |
|
| 2016 |
Peyrin-Biroulet L, Van Assche G, Armuzzi A, Garcia-Alvarez L, Lara N, Black CM, Khalifa A, Cornillie F, Kachroo S. Implementing the concept of Continuous Clinical Response into clinical practice for ulcerative colitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 27720910 DOI: 10.1016/J.Cgh.2016.10.001 |
0.352 |
|
| 2016 |
Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients with Inflammatory Bowel Diseases. Gastroenterology. PMID 27720840 DOI: 10.1053/J.Gastro.2016.09.046 |
0.383 |
|
| 2016 |
Park JH, Jeong DY, Peyrin-Biroulet L, Eisenhut M, Shin JI. Insight into the role of TSLP in inflammatory bowel diseases. Autoimmunity Reviews. PMID 27697608 DOI: 10.1016/J.Autrev.2016.09.014 |
0.4 |
|
| 2016 |
Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD. Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. The American Journal of Gastroenterology. PMID 27670599 DOI: 10.1038/Ajg.2016.433 |
0.384 |
|
| 2016 |
Peyrin-Biroulet L, Gower-Rousseau C. The IBD Disability Index should become a Major Secondary Endpoint in Clinical Practice and in Clinical Trials. Journal of Crohn's & Colitis. 10: 1375-1377. PMID 27664272 DOI: 10.1093/Ecco-Jcc/Jjw156 |
0.448 |
|
| 2016 |
Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, et al. 3. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. Journal of Crohn's & Colitis. PMID 27660341 DOI: 10.1093/Ecco-Jcc/Jjw168 |
0.336 |
|
| 2016 |
Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. PMID 27585411 DOI: 10.1097/Mib.0000000000000909 |
0.358 |
|
| 2016 |
Collins M, Sarter H, Gower-Rousseau C, Koriche D, Libier L, Nachury M, Cortot A, Zerbib P, Blanc P, Desreumaux P, Colombel JF, Peyrin-Biroulet L, Pineton de Chambrun G. Previous exposure to multiple anti-TNF is associated with decreased efficiency in preventing postoperative Crohn's disease recurrence. Journal of Crohn's & Colitis. PMID 27578800 DOI: 10.1093/Ecco-Jcc/Jjw151 |
0.424 |
|
| 2016 |
Marchal-Bressenot A, Scherl A, Salleron J, Peyrin-Biroulet L. A practical guide to assess the Nancy histological index for UC. Gut. PMID 27566129 DOI: 10.1136/Gutjnl-2016-312722 |
0.358 |
|
| 2016 |
Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Alimentary Pharmacology & Therapeutics. PMID 27534519 DOI: 10.1111/Apt.13763 |
0.608 |
|
| 2016 |
Hochart A, Gower-Rousseau C, Sarter H, Fumery M, Ley D, Spyckerelle C, Peyrin-Biroulet L, Laberenne JE, Vasseur F, Savoye G, Turck D. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut. PMID 27489240 DOI: 10.1136/Gutjnl-2016-311970 |
0.378 |
|
| 2016 |
Cheddani H, Dauchet L, Fumery M, Charpentier C, Marie Bouvier A, Dupas JL, Pariente B, Peyrin-Biroulet L, Savoye G, Gower-Rousseau C. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. The American Journal of Gastroenterology. 111: 1428-1436. PMID 27481308 DOI: 10.1038/Ajg.2016.304 |
0.425 |
|
| 2016 |
Peyrin-Biroulet L, Danese S. Editorial Personalized Medicine in Inflammatory Bowel Diseases: Myth or Reality? Current Drug Targets. PMID 27469468 DOI: 10.2174/1389450117999160713161226 |
0.427 |
|
| 2016 |
Sandborn W, Colombel JF, D'Haens G, Ghosh S, Panaccione R, Panés J, Travis S, Peyrin-Biroulet L. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 27464592 DOI: 10.1016/J.Cgh.2016.07.008 |
0.378 |
|
| 2016 |
Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, García-Álvarez L, Lara N, Black CM, Kachroo S. Systematic review of tumour necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 27392760 DOI: 10.1016/J.Cgh.2016.06.025 |
0.435 |
|
| 2016 |
Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opinion On Biological Therapy. 16: 1277-90. PMID 27329436 DOI: 10.1080/14712598.2016.1203897 |
0.45 |
|
| 2016 |
Taleban S, Elquza E, Gower-Rousseau C, Peyrin-Biroulet L. Cancer and inflammatory bowel disease in the elderly. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. 48: 1105-11. PMID 27289334 DOI: 10.1016/J.Dld.2016.05.006 |
0.337 |
|
| 2016 |
Wisniewski A, Danese S, Peyrin-Biroulet L. Evolving treatment algorithms in Crohn's Disease. Current Drug Targets. PMID 27280794 DOI: 10.2174/1389450117666160607075557 |
0.425 |
|
| 2016 |
Conroy G, Clerc-Urmès I, Allen PB, Baumann C, Peyrin-Biroulet L. What Proportion of Patients With Inflammatory Bowel Disease Want to Stop Infliximab Therapy? Inflammatory Bowel Diseases. PMID 27271494 DOI: 10.1097/Mib.0000000000000837 |
0.458 |
|
| 2016 |
Danese S, Hart A, Dignass A, Louis E, D'Haens G, Dotan I, Rogler G, D'Agay L, Iannacone C, Peyrin-Biroulet L. Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. Bmj Open Gastroenterology. 3: e000092. PMID 27239329 DOI: 10.1136/Bmjgast-2016-000092 |
0.33 |
|
| 2016 |
Allocca M, Fiorino G, Gilardi D, Preatoni P, Papa A, Peyrin-Biroulet L, Danese S. Biologic therapies in ulcerative colitis: primi inter pares? Current Drug Targets. PMID 27231106 DOI: 10.2174/1389450117666160527142719 |
0.34 |
|
| 2016 |
Nahon S, Lahmek P, Paupard T, Lesgourgues B, Chaussade S, Peyrin-Biroulet L, Abitbol V. Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients. Digestive Diseases and Sciences. 61: 3278-3284. PMID 27207180 DOI: 10.1007/S10620-016-4189-Z |
0.386 |
|
| 2016 |
Fumery M, Pariente B, Sarter H, Charpentier C, Armengol Debeir L, Dupas JL, Coevoet H, Peyrin-Biroulet L, dʼAgay L, Gower-Rousseau C, Savoye G. Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study. Inflammatory Bowel Diseases. PMID 27206018 DOI: 10.1097/Mib.0000000000000821 |
0.359 |
|
| 2016 |
Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 14: 1385-1397.e10. PMID 27189910 DOI: 10.1016/J.Cgh.2016.04.039 |
0.42 |
|
| 2016 |
Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X. French national consensus clinical guidelines for the management of ulcerative colitis. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. 48: 726-33. PMID 27158125 DOI: 10.1016/J.Dld.2016.03.029 |
0.388 |
|
| 2016 |
Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV. Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 14: 1439-44. PMID 27155552 DOI: 10.1016/J.Cgh.2016.04.031 |
0.446 |
|
| 2016 |
Lopez A, Collet-Fenetrier B, Belle A, Peyrin-Biroulet L. Patient's knowledge and fear about colorectal cancer risk in inflammatory bowel disease. Journal of Digestive Diseases. PMID 27129893 DOI: 10.1111/1751-2980.12356 |
0.404 |
|
| 2016 |
Salleron J, Peyrin-Biroulet L. Reply to: Dr Macaluso's Letter. Journal of Crohn's & Colitis. 10: 1452. PMID 27122595 DOI: 10.1093/Ecco-Jcc/Jjw097 |
0.369 |
|
| 2016 |
Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology. 10: 915-27. PMID 27043489 DOI: 10.1586/17474124.2016.1174064 |
0.422 |
|
| 2016 |
Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. Journal of Crohn's & Colitis. 10: 1015-23. PMID 27022161 DOI: 10.1093/Ecco-Jcc/Jjw067 |
0.319 |
|
| 2016 |
Blotière PO, Rudant J, Barré A, Racine A, Weill A, Peyrin-Biroulet L, Carbonnel F, Alla F. Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013). Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. 48: 620-5. PMID 27017107 DOI: 10.1016/J.Dld.2016.02.022 |
0.458 |
|
| 2016 |
Peyrin-Biroulet L, Van Assche G, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, et al. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 27012447 DOI: 10.1016/J.Dld.2016.01.013 |
0.366 |
|
| 2016 |
Roblin X, Williet N, Peyrin-Biroulet L. Thiopurine Metabolism in the Era of Combotherapy. Inflammatory Bowel Diseases. 22: 1496-501. PMID 26978723 DOI: 10.1097/Mib.0000000000000737 |
0.366 |
|
| 2016 |
Germain A, Guéant RM, Chamaillard M, Allen PB, Bresler L, Guéant JL, Peyrin-Biroulet L. NOD2 gene variant is a risk factor for postoperative complications in patients with Crohn's disease: A genetic association study. Surgery. PMID 26946932 DOI: 10.1016/J.Surg.2016.01.013 |
0.716 |
|
| 2016 |
Salleron J, Danese S, D'Agay L, Peyrin-Biroulet L. Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge. Journal of Crohn's & Colitis. 10: 1096-102. PMID 26944416 DOI: 10.1093/Ecco-Jcc/Jjw068 |
0.355 |
|
| 2016 |
Van Assche G, Peyrin-Biroulet L, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, et al. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 26935454 DOI: 10.1016/J.Dld.2016.01.011 |
0.426 |
|
| 2016 |
Peyrin-Biroulet L, Danese S. Early Combined Immunosuppression in Crohn's Disease: Acting Rather Than REACTing. Gastroenterology. 150: 1040-1. PMID 26922865 DOI: 10.1053/J.Gastro.2016.02.056 |
0.403 |
|
| 2016 |
Poullenot F, Seksik P, Beaugerie L, Amiot A, Nachury M, Abitbol V, Stefanescu C, Reenaers C, Fumery M, Pelletier AL, Nancey S, Peyrin-Biroulet L, Bourreille A, Hébuterne X, Brixi H, et al. Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. Inflammatory Bowel Diseases. 22: 1362-9. PMID 26919458 DOI: 10.1097/Mib.0000000000000741 |
0.42 |
|
| 2016 |
Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, et al. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 14: 1593-1601.e2. PMID 26917043 DOI: 10.1016/J.Cgh.2016.02.016 |
0.39 |
|
| 2016 |
Allen PB, Peyrin-Biroulet L. Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. Expert Review of Clinical Immunology. PMID 26900725 DOI: 10.1586/1744666X.2016.1154789 |
0.404 |
|
| 2016 |
Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology & Therapeutics. 159: 110-9. PMID 26808166 DOI: 10.1016/J.Pharmthera.2016.01.001 |
0.373 |
|
| 2016 |
Peyrin-Biroulet L, Salleron J, Filippi J, Reenaers C, Antunes O, Filipe V, Louis E, Hébuterne X, Roblin X. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. Journal of Crohn's & Colitis. 10: 516-24. PMID 26802084 DOI: 10.1093/Ecco-Jcc/Jjw008 |
0.428 |
|
| 2016 |
Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opinion On Drug Safety. 15: 493-501. PMID 26799429 DOI: 10.1517/14740338.2016.1145653 |
0.353 |
|
| 2016 |
Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. Journal of Crohn's & Colitis. 10: 395-401. PMID 26783344 DOI: 10.1093/Ecco-Jcc/Jjv227 |
0.309 |
|
| 2016 |
Bressenot AM, Peyrin-Biroulet L. Letter: histological assessment of disease activity in ulcerative colitis--the problem of score evaluation and validation; authors' reply. Alimentary Pharmacology & Therapeutics. 43: 439-439. PMID 26782113 DOI: 10.1111/Apt.13489 |
0.35 |
|
| 2016 |
Bonovas S, Fiorino G, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L, Danese S. Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine. 95: e2308. PMID 26765407 DOI: 10.1097/Md.0000000000002308 |
0.308 |
|
| 2016 |
Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S. Preventing Collateral Damage in Crohn's Disease: The Lémann Index. Journal of Crohn's & Colitis. 10: 495-500. PMID 26744441 DOI: 10.1093/Ecco-Jcc/Jjv240 |
0.419 |
|
| 2016 |
Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, et al. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. Gastroenterology. 150: 380-388.e4. PMID 26632520 DOI: 10.1053/J.Gastro.2015.10.050 |
0.417 |
|
| 2016 |
Fumery M, Duricova D, Gower-Rousseau C, Annese V, Peyrin-Biroulet L, Lakatos PL. Review article: the natural history of paediatric‐onset ulcerative colitis in population‐based studies Alimentary Pharmacology & Therapeutics. 43: 346-355. PMID 26582737 DOI: 10.1111/Apt.13478 |
0.405 |
|
| 2016 |
Penninck E, Fumery M, Armengol-Debeir L, Sarter H, Savoye G, Turck D, Pineton de Chambrun G, Vasseur F, Dupas JL, Lerebours E, Colombel JF, Peyrin-Biroulet L, Gower-Rousseau C. Postoperative Complications in Pediatric Inflammatory Bowel Disease: A Population-based Study. Inflammatory Bowel Diseases. 22: 127-33. PMID 26355466 DOI: 10.1097/Mib.0000000000000576 |
0.412 |
|
| 2016 |
Guinet-Charpentier C, Champigneulle J, Williet N, Peyrin-Biroulet L, Morali A. The association of autoimmune diseases with pediatric ulcerative colitis does not influence its disease course. Scandinavian Journal of Gastroenterology. 51: 33-40. PMID 26152794 DOI: 10.3109/00365521.2015.1058415 |
0.438 |
|
| 2016 |
Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 14: 348-354.e17. PMID 26071941 DOI: 10.1016/J.Cgh.2015.06.001 |
0.465 |
|
| 2016 |
Melhem H, Hansmannel F, Bressenot A, Battaglia-Hsu SF, Billioud V, Alberto JM, Gueant JL, Peyrin-Biroulet L. Methyl-deficient diet promotes colitis and SIRT1-mediated endoplasmic reticulum stress. Gut. 65: 595-606. PMID 25608526 DOI: 10.1136/Gutjnl-2014-307030 |
0.705 |
|
| 2016 |
Khalid JM, Peyrin-Biroulet L, Armuzzi A, Gisbert JP, Nguyen G, Bokemeyer B, Lindsay J, Smyth M, Munsaka M, Ramagopalan S. Predictors of Non-response or Loss of Response to Tumour Necrosis Factor Antagonist Therapies in Inflammatory Bowel Disease American Journal of Gastroenterology. 111: S316. DOI: 10.14309/00000434-201610001-00699 |
0.377 |
|
| 2016 |
Armuzzi A, Lindsay J, Mody R, Bokemeyer B, Gisbert J, Peyrin-Biroulet L, Nguyen G, Siebenaler J, Åkerborg Ö, Smyth M, Rathmell A. PTH-071 Indicators of Suboptimal Therapy Among Crohn’s Disease Patients Treated with Tumour Necrosis Factor Antagonists: Results from A Multi-National Study Gut. 65: A254.1-A254. DOI: 10.1136/Gutjnl-2016-312388.477 |
0.363 |
|
| 2016 |
Lindsay J, Gisbert J, Mody R, Peyrin-Biroulet L, Armuzzi A, Bokemeyer B, Nguyen G, Siebenaler J, Åkerborg Ö, Smyth M, Rathmell A. PTH-070 A Multinational Study to Determine Indicators of Suboptimal Therapy Among Ulcerative Colitis Patients Treated with Tumour Necrosis Factor Antagonists Gut. 65: A253-A254. DOI: 10.1136/Gutjnl-2016-312388.476 |
0.36 |
|
| 2016 |
Reinisch S, Schweiger K, Pablik E, Collet-Fenetrier B, Peyrin-Biroulet L, Alfaro I, Panés J, Moayyedi P, Reinisch W. An index with improved diagnostic accuracy for the diagnosis of Crohn's disease derived from the Lennard-Jones criteria Alimentary Pharmacology & Therapeutics. 44: 601-611. DOI: 10.1111/Apt.13727 |
0.315 |
|
| 2016 |
Siegel C, Whitman C, Spiegel B, Feagan B, Sands B, Loftus E, Panaccione R, D'Haens G, Bernstein C, Gearry R, Ng S, Mantzaris G, Sartor B, Silverberg M, Riddell R, ... ... Peyrin-Biroulet L, et al. Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease : results of an IOIBD specialist panel Journal of Crohns & Colitis. 10. DOI: 10.1093/Ecco-Jcc/Jjw019.104 |
0.432 |
|
| 2016 |
Siegel CA, Whitman CB, Spiegel B, Feagan BG, Sands BE, Loftus EV, Panaccione R, D'Haens GR, Bernstein CN, Gearry RB, Ng SC, Mantzaris GJ, Sartor RB, Silverberg MS, Riddell R, ... ... Peyrin-Biroulet L, et al. Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel Gastroenterology. 150: S991. DOI: 10.1016/S0016-5085(16)33355-8 |
0.433 |
|
| 2016 |
Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollelis E, Fumery M, Pariente B, Flamant M, Bourreille A, Bonnaud G, Mathieu S, Thevenin A, Duruy M, Filippi J, Lhopital F, ... ... Peyrin-Biroulet L, et al. Tu1940 Patients' Point of View Regarding Acceptability and Usefulness of Inflammatory Bowel Diseases Monitoring Tools: Results From a Nationwide Multicenter Study (the ACCEPT Study) Gastroenterology. 150. DOI: 10.1016/S0016-5085(16)33333-9 |
0.435 |
|
| 2016 |
Amiot A, Grimaud J, Treton X, Filippi J, Pariente B, Peyrin-Biroulet L, Boureille A, Buisson A, Carbonnel F, Bourrier A, Nancey S, Roblin X, Marteau PR, Altwegg R, Moreau J, et al. Mo1896 The Real-Life Experience of Vedolizumab Efficacy and Safety in Crohn's Disease: A Prospective Observational Multicenter Cohort Study Gastroenterology. 150. DOI: 10.1016/S0016-5085(16)32738-X |
0.353 |
|
| 2016 |
Michetti PF, Peyrin-Biroulet L, Silverberg MS, Louis E, Weinman J, Sommer J, Petersson JH, Pappalardo B, Nurwakagari P. Mo1840 Impact of Age on Beliefs About and Adherence to Medications in Patients With Inflammatory Bowel Disease: Results From the ALIGN Study Gastroenterology. 150. DOI: 10.1016/S0016-5085(16)32682-8 |
0.389 |
|
| Show low-probability matches. |